<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0117">
    <title>98 Arboviruses</title>
    <sect1 id="ch0117s0001">
      <title>98 Arboviruses</title>
      <anchor id="ch0117s0001a0001"/>
      <anchor id="ch0117s0001a0002"/>
      <para id="ch0117s0001p0001" role="chapterAuthor">ELIZABETH A. HUNSPERGER, HOLLY R. HUGHES, JANA M. RITTER, AND AARON C. BRAULT</para>
      <sect2 id="ch0117s0001s0001">
        <title>TAXONOMY</title>
        <anchor id="ch0117s0001s0001a0001"/>
        <anchor id="ch0117s0001s0001a0002"/>
        <para id="ch0117s0001s0001p0001">Arthropod-borne viruses (arboviruses) are transmitted to vertebrate hosts through the bites of infected arthropods and cause over 80 diseases in humans. These viruses have been grouped according to their arthropod vectors: mosquitoes, ticks, sand flies, midges, and others (<anchor id="ch0117s0001s0001a0003"/><link linkend="ch0117s0001s0002a0007">Table 1</link>). There are ~532 taxonomically diverse viruses in nine distinct families: <emphasis>Togaviridae, Flaviviridae, Peribunyaviridae, Phenuiviridae, Nairoviridae, Reoviridae, Rhabdoviridae, Orthomyxoviridae</emphasis>, and <emphasis>Asfaviridae.</emphasis> Some of these families are known to infect only arthropods, with no other known host. The medically important arboviruses are found primarily within the families <emphasis>Togaviridae, Flaviviridae, Peribunyaviridae, Phenuiviridae</emphasis>, and <emphasis>Nairoviridae</emphasis>, which are the focus of this chapter. In these five families, there are more than 300 viruses, of which as many as 70 are medically important (<link linkend="ch0117s0009s0002li0001">1</link>–<link linkend="ch0117s0009s0002li0004">4</link>). The complete list and characterization of the first discovery and isolation of these viruses can be found in The International Catalog of Arboviruses (<ulink url="https://wwwn.cdc.gov/arbocat/">https://wwwn.cdc.gov/arbocat/</ulink>).</para>
      </sect2>
      <sect2 id="ch0117s0001s0002">
        <title>DESCRIPTION OF THE AGENT</title>
        <anchor id="ch0117s0001s0002a0001"/>
        <anchor id="ch0117s0001s0002a0002"/>
        <para id="ch0117s0001s0002p0001">Arboviruses are RNA viruses of either positive or negative polarity (with the exception of African swine fever virus, in the family<emphasis>Asfaviridae</emphasis>). They are enveloped viruses with single-strand and/or segmented RNA genomes and are capable of replication in both insect and mammalian cells. Since most are enveloped viruses, they are not very stable in the environment and cannot survive outside their hosts for very long. Arboviruses range from 40 to 100 nm in size and have an RNA genome of approximately 9 to 22 kb. Many medically important arboviruses have been sequenced (full length or partial, e.g., structural genes), and the sequences are available on GenBank for diagnostic test and vaccine development.</para>
        <para id="ch0117s0001s0002p0002">Arbovirus replication takes place in the cytoplasm of susceptible cells following viral entry. For most arboviruses, there are multiple receptors for viral entry that are not well characterized. Some common receptors include heparin sulfate proteoglycans and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) (<link linkend="ch0117s0009s0002li0005">5</link>, <link linkend="ch0117s0009s0002li0006">6</link>). Following viral entry via endosomes, the virus is released into the cytoplasm, typically by a low-pH-induced irreversible conformational change of the structural proteins. For nonsegmented viruses, RNA then circularizes through attachment of the 3′ and 5′ nontranslated regions, forming concatemers that facilitate replication of the virus (<link linkend="ch0117s0009s0002li0007">7</link>).</para>
        <para id="ch0117s0001s0002p0003">The family<emphasis>Flaviviridae</emphasis> has four genera: <emphasis>Hepacivirus, Flavivirus, Pegivirus</emphasis>, and <emphasis>Pestivirus.</emphasis> Only the viruses in the genus <emphasis>Flavivirus</emphasis> are known to be transmitted through arthropod vectors. These viruses are positive-sense, nonsegmented RNA viruses that are ~40 to 50 nm in diameter and whose genome is between 9 and 12 kb in length. The genome encodes three structural proteins (encoding capsid [C], membrane [M; designated “prM” in its immature state], and envelope [E] proteins) and seven nonstructural genes (encoding nonstructural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5), flanked by a 5′ and 3′ untranslated region (<anchor id="ch0117s0001s0002a0003"/><link linkend="ch0117s0001s0002a0011">Fig. 1A</link>). All genes are essential for viral replication, and some are highly conserved, such as NS3 and NS5. Upon viral entry into a susceptible cell through receptor-mediated endocytosis, pH-induced conformational change of the structural gene product allows the virus to be released into the cytoplasm. The viral RNA is then translated into a single polypeptide. The virus egresses through the secretory pathway.</para>
        <para id="ch0117s0001s0002p0004">The family<emphasis>Togaviridae</emphasis> is composed of a single genus, <emphasis>Alphavirus.</emphasis> Viruses making up this genus are positive-sense nonsegmented RNA viruses ~60 to 70 nm in diameter whose genome ranges between 10 and 12 kb. The viruses all contain three structural genes (E1, E2, and C) and four nonstructural genes (nsP1, nsP2, nsP3, and nsP4). These viruses have a 5′ cap and a polyadenylated tail (<link linkend="ch0117s0001s0002a0011">Fig. 1B</link>). Since these viruses are structurally similar to mRNA in animal cells, the RNA of these viruses is infectious. Like flaviviruses, these viruses infect susceptible cells through receptor-mediated entry, where the viruses are released from the endosome due to conformation change of the E1 protein, inducing acid-dependent fusion. Replication occurs in the cell cytoplasm. Egress of the virus is through preformed nucleocapsids with E1 and E2 glycoproteins on the plasma membrane.</para>
        <anchor id="ch0117s0001s0002a0004"/>
        <beginpage pagenum="1895"/>
        <anchor id="ch0117s0001s0002a0005"/>
        <beginpage pagenum="1896"/>
        <anchor id="ch0117s0001s0002a0006"/>
        <beginpage pagenum="1897"/>
        <table id="ch0117s0001s0002t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0117s0001s0002a0007"/><link linkend="ch0117s0001s0001a0003">TABLE 1</link></phrase></emphasis> Characteristics of arboviruses affecting humans
</title>
          
          <tgroup cols="7">
            <tbody>
              <row>
                <entry>Family and genus</entry>
                <entry><phrase role="center">Virus common name</phrase>
                </entry>
                <entry><phrase role="center">Vector</phrase>
                </entry>
                <entry><phrase role="center">Vaccine</phrase>
                </entry>
                <entry><phrase role="center">Geographical distribution<superscript><link linkend="ch0117s0001s0002a0009"><emphasis>a</emphasis></link></superscript></phrase>
                  <anchor id="ch0117s0001s0002a0008"/>
                </entry>
                <entry><phrase role="center">Tropism/complication(s)</phrase>
                </entry>
                <entry><phrase role="center">Other risk factors</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>Flaviviridae</emphasis>
                </entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Flavivirus</emphasis>
                </entry>
                <entry>Bussuquara</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>CSA</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Dengue</entry>
                <entry>Mosquito</entry>
                <entry>Denvax</entry>
                <entry>A, NA, CSA, I/SEA, O</entry>
                <entry>Viscerotropism/hemorrhage, encephalitis</entry>
                <entry>Transfusion; transplacental transmission; sickle cell anemia</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Ilheus</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>CSA</entry>
                <entry>Encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Japanese encephalitis</entry>
                <entry>Mosquito</entry>
                <entry>SJE-VAX /Ixiaro</entry>
                <entry>I/SEA</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Kyasanur Forest</entry>
                <entry>Tick</entry>
                <entry>None</entry>
                <entry>I/SEA</entry>
                <entry>Viscerotropism/hemorrhage, encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Murray Valley</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>O</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Omsk hemorrhagic fever</entry>
                <entry>Tick</entry>
                <entry>None</entry>
                <entry>R</entry>
                <entry>Viscerotropism/hemorrhage</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Powassan</entry>
                <entry>Tick</entry>
                <entry>None</entry>
                <entry>NA</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Rocio</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>CSA</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>St. Louis encephalitis</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>NA, CSA</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Tick-borne encephalitis</entry>
                <entry>Tick</entry>
                <entry>Encepur/TBE-Immun</entry>
                <entry>E</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry>Unpasteurized dairy milk</entry>
              </row>
              <row>
                <entry></entry>
                <entry>West Nile/Kunjin</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>NA, CSA, E, I/SEA, O</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry>Transfusion; organ donation; transplacental transmission</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Yellow fever</entry>
                <entry>Mosquito</entry>
                <entry>YF-VAX</entry>
                <entry>A, CSA</entry>
                <entry>Viscerotropism/hemorrhage, encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Zika</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>A, I/SEA, CSA, NA</entry>
                <entry>Viscerotropism/neurotropism</entry>
                <entry>Transplacental/sexual transmission</entry>
              </row>
              <row>
                <entry><emphasis>Nairoviridae</emphasis>
                </entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Orthonairovirus</emphasis>
                </entry>
                <entry>Crimean-Congo hemorrhagic fever</entry>
                <entry>Tick</entry>
                <entry>None</entry>
                <entry>A</entry>
                <entry>Viscerotropism/hemorrhagic</entry>
                <entry>Potential nosocomial agent</entry>
              </row>
              <row>
                <entry><emphasis>Orthomyxoviridae</emphasis>
                </entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Thogotovirus</emphasis>
                </entry>
                <entry>Bourbon</entry>
                <entry>Tick</entry>
                <entry>None</entry>
                <entry>NA</entry>
                <entry>Possible viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Dhori</entry>
                <entry>Tick</entry>
                <entry>None</entry>
                <entry>I/SEA</entry>
                <entry>Viscerotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Thogotovirus</entry>
                <entry>Tick</entry>
                <entry>None</entry>
                <entry>A</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Peribunyaviridae</emphasis>
                </entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Orthobunyavirus</emphasis>
                </entry>
                <entry>Bwamba</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>A</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Bunyamwera</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>A</entry>
                <entry>Viscerotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Cache Valley virus</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>NA, CSA</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Guaroa</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>CSA</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Ilesha</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>A</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Jamestown Canyon</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>NA</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>La Crosse</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>NA</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Oropouche</entry>
                <entry>Midge</entry>
                <entry>None</entry>
                <entry>CSA</entry>
                <entry>Viscerotropism/hemorrhage, encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Tahyna</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>E</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Tataguine</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>A</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Phenuiviridae</emphasis>
                </entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Bandavirus</emphasis>
                </entry>
                <entry>Heartland</entry>
                <entry>Tick</entry>
                <entry>None</entry>
                <entry>NA</entry>
                <entry>Possible viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Severe fever with thrombocytopenia syndrome</entry>
                <entry>Tick</entry>
                <entry>None</entry>
                <entry>SEA</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Phlebovirus</emphasis>
                </entry>
                <entry>Rift Valley fever</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>A</entry>
                <entry>Viscerotropism/hemorrhage, encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Sand fly fever (Naples, Sicilian)</entry>
                <entry>Sand fly</entry>
                <entry>None</entry>
                <entry>E, I/SEA</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Toscana</entry>
                <entry>Sand fly</entry>
                <entry>None</entry>
                <entry>E</entry>
                <entry>Neurotropism/aseptic meningitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Reoviridae</emphasis>
                </entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Coltivirus</emphasis>
                </entry>
                <entry>Colorado tick fever</entry>
                <entry>Tick</entry>
                <entry>None</entry>
                <entry>NA</entry>
                <entry>Viscerotropism/hemorrhage, encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Eyach virus</entry>
                <entry>Tick</entry>
                <entry>None</entry>
                <entry>NA</entry>
                <entry>Viscerotropism/hemorrhage, encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Rhabdoviridae</emphasis>
                </entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Vesiculovirus</emphasis>
                </entry>
                <entry>Piry</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>CSA</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Vesicular stomatitis</entry>
                <entry>Sand fly</entry>
                <entry>None</entry>
                <entry></entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Togaviridae</emphasis>
                </entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
                <entry></entry>
              </row>
              <row>
                <entry><emphasis>Alphavirus</emphasis>
                </entry>
                <entry>Barmah Forest</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry></entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Chikungunya</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>A, I/SEA, CSA</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Eastern equine encephalitis</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>NA, CSA</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Mayaro</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>CSA</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>O’nyong-nyong</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>A</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Ross River</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>O</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Semliki Forest</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>A</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Sindbis</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>A</entry>
                <entry>Viscerotropism</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Venezuelan equine encephalitis</entry>
                <entry>Mosquito</entry>
                <entry>TC-83</entry>
                <entry>NA, CSA</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry></entry>
              </row>
              <row>
                <entry></entry>
                <entry>Western equine encephalitis</entry>
                <entry>Mosquito</entry>
                <entry>None</entry>
                <entry>NA</entry>
                <entry>Neurotropism/encephalitis</entry>
                <entry>Transplacental transmission</entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para id="ch0117s0001s0002p0005" role="table-footnote"><superscript><link linkend="ch0117s0001s0002a0008"><emphasis>a</emphasis></link></superscript><anchor id="ch0117s0001s0002a0009"/>A, Africa and Middle East; NA, North America; CSA, Central and/or South America; E, Europe and/or continental Asia; I/SEA, India and Southeast Asia, including China and Japan; O, Oceania; R, Russia.</para>
        <figure id="ch0117s0001s0002f0001"><title><anchor id="ch0117s0001s0002a0010"/><phrase role="figureLabel"><anchor id="ch0117s0001s0002a0011"/><link linkend="ch0117s0001s0002a0003">FIGURE 1</link></phrase> (A) Flavivirus genome; (B) alphavirus genome; (C) bunyavirus genome. UTR, untranslated region; RdRP, RNA-dependent RNA polymerase.
</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0117f05.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <para id="ch0117s0001s0002p0006">The order<emphasis>Bunyavirales</emphasis> is composed of 13 families, three of which are known to contain human pathogens: <emphasis>Peribunyaviridae, Phenuiviridae</emphasis>, and <emphasis>Nairoviridae.</emphasis> Only viruses in the genera <emphasis>Orthobunyavirus, Orthonairovirus, Bandavirus</emphasis>, and <emphasis>Phlebovirus</emphasis> are transmitted through an arthropod vector; their size ranges from ~90 to 100 nm, and their segmented genome is ~10 to 22 kb. These viruses are negative-sense single-stranded RNA viruses composed of three segments (L, M, and S). The L (large) segment encodes the L protein, including the RNA-dependent RNA polymerase (RdRp) domain, and the M (medium) segment encodes the viral glycoproteins; both are negative sense. In contrast, the S (small) segment encodes the nucleocapsid protein in the negative sense and may encode a nonstructural protein in an overlapping reading frame in orthobunyaviruses. Alternatively, phenuiviral S segments use an ambisense strategy and encode for the nonstructural protein in the positive sense (<link linkend="ch0117s0001s0002a0011">Fig. 1C</link>). Genetic reassortment can occur between members of the serogroup in the genus <emphasis>Orthobunyavirus</emphasis> but not between members of different serogroups in the same genus.</para>
        <para id="ch0117s0001s0002p0007">Some arboviruses have developed divergent genomic sequences within species driven by transmission within a specific geographical location, and these viruses are referred to as genotypes, subtypes, or lineages. These genotypes result from the evolution of these virus species within restricted ecological niches, resulting in evolutionary divergence for improved adaptation. Genotypes have been described for virus species in genera in several families: in<emphasis>Flavivirus</emphasis> (<emphasis>Flaviviridae</emphasis>), Japanese encephalitis virus (JEV), dengue virus (DENV), yellow fever virus (YFV), and West Nile virus (WNV); in <emphasis>Alphavirus</emphasis> (<emphasis>Togaviridae</emphasis>), Eastern equine encephalitis virus (EEEV), Western equine encephalitis virus (WEEV), and Venezuelan equine encephalitis virus (VEEV); and in <emphasis>Orthobunyavirus</emphasis> (<emphasis>Peribunyaviridae</emphasis>), La Crosse virus (LACV). Within each family of viruses, there is significant nucleic acid homology. The most conserved genes are those corresponding to the RdRp and the nonstructural genes essential for RNA replication. This relatively high level of nucleic acid homology between families of viruses results in gene products that share epitopes targeted by the host’s neutralizing antibodies, giving rise to significant cross-reactivity within some arbovirus families. However, these cross-reactive epitopes are often not cross-protective and cause significant challenges in the interpretation of immunodiagnostic tests.</para>
        <para id="ch0117s0001s0002p0008">Arboviruses evade the host innate immune response by blocking the interferon response early in the infection. In particular for flaviviruses, type I interferons (alpha/beta interferons) are key mediators of innate antiviral responses which are inhibited by the RdRp NS5 (<link linkend="ch0117s0009s0002li0008">8</link>). A similar antagonism of the type I interferon response has been demonstrated for Rift Valley fever virus NSs protein (<link linkend="ch0117s0009s0002li0009">9</link>). This allows the virus to replicate in the susceptible host to titers sufficient to reinfect an arthropod vector and continue the cycle of transmission. In some instances, the host immune response can further amplify viral titers in the host by facilitating viral entry through Fc receptors. This is often referred to as antibody-dependent enhancement and has been best described for dengue viruses (<link linkend="ch0117s0009s0002li0010">10</link>).</para>
        <anchor id="ch0117s0001s0002a0012"/>
        <beginpage pagenum="1898"/>
      </sect2>
      <sect2 id="ch0117s0001s0003">
        <title>EPIDEMIOLOGY AND TRANSMISSION</title>
        <anchor id="ch0117s0001s0003a0001"/>
        <anchor id="ch0117s0001s0003a0002"/>
        <para id="ch0117s0001s0003p0001">Many mosquito-borne arboviruses are most commonly transmitted in tropical and subtropical regions of the world and are highly dependent on the presence of the vector and an amplifying host. Currently, approximately 40% of the world’s population live in tropical regions and are at risk of acquiring an arbovirus infection. The cycle of transmission can be either urban (mosquito to person to mosquito), sylvatic (mosquito to nonhuman primate to mosquito), or epizootic (mosquito to vertebrate to mosquito, where humans are dead-end incidental hosts). Arbovirus transmission is seasonal, and the highest transmission is commensurate with the abundance of the vector, in the hot and rainy seasons for most mosquito-borne viruses. For arboviruses that are endemic in a population, their transmission can be cyclical; there is sustained annual transmission, with periodic epidemics occurring every 2 to 20 years depending on the host immunity status, vector, virus, and virus reintroduction rates. Often there is no significant difference in infection rate by age or sex; however, in regions of high endemicity, as is observed with dengue viruses, where viral transmission is annual and persistent, the infection rate in younger individuals (&lt;10 years old) tends to be higher than that in adults, because they reflect the susceptible population (<link linkend="ch0117s0009s0002li0011">11</link>).</para>
        <anchor id="ch0117s0001s0003a0003"/>
        <beginpage pagenum="1899"/>
        <para id="ch0117s0001s0003p0002">The transmission cycle of arboviruses includes an arthropod vector and a vertebrate animal reservoir as the amplifying host, and some have a dead-end or incidental host. Some viruses have evolved an urban and a sylvatic transmission cycle; this has been well documented for chikungunya virus (CHIKV) and YFV. Arboviruses may cause seasonal epidemics, which are often linked to the abundance of the vector, intermediate amplifying hosts, susceptible hosts, and introductions of new genotypes, subtypes, or lineages. Humans have become the principal amplifying host without the need for an intermediate vertebrate amplifying host for arboviruses such as DENV, ZIKV, YFV, and CHIKV. The principal vectors are container-breeding species that require a very small volume of water to lay their eggs; thus, control of larval and adult populations is very difficult. Many factors contribute to the expansion of arboviruses, including travel and urbanization of the human population with uncontrolled urban growth, which contributes to an increase in mosquito breeding sites. In addition, the lack of vector control measures within this environment contributes to this vicious circle of sustained transmission and episodic epidemics.</para>
        <para id="ch0117s0001s0003p0003">Most arbovirus infection occurs through the bite of an infected arthropod; however, there are other sources of arbovirus infection, including blood transfusion, organ donation, transplacental transmission, breast milk, laboratory acquisition, and sexual transmission. Infection through organ donation was best described for WNV following its emergence in the United States, where transplantation of infected organs caused fatalities in organ recipients (<link linkend="ch0117s0009s0002li0012">12</link>). These studies prompted the investigation of transmission of other arbovirus infections via blood and organ donations, especially DENV, ZIKV, and CHIKV, which cause a high rate of asymptomatic infections (75%) with sufficient viral titers to infect transfusion or organ recipients (<link linkend="ch0117s0009s0002li0013">13</link>). Other studies have described the presence of CHIKV, WNV, ZIKV, and DENV in breast milk, but vertical transmission through this route is still not well characterized (<link linkend="ch0117s0009s0002li0014">14</link>–<link linkend="ch0117s0009s0002li0017">17</link>). Sexual transmission has been extensively documented only for ZIKV (<link linkend="ch0117s0009s0002li0018">18</link>, <link linkend="ch0117s0009s0002li0019">19</link>); however, a number of other arboviruses have demonstrated some evidence of potential sexual transmission, but data to support this form of transmission are lacking (<link linkend="ch0117s0009s0002li0020">20</link>, <link linkend="ch0117s0009s0002li0021">21</link>).</para>
        <para id="ch0117s0001s0003p0004">Historically, arboviruses were geographically restricted and had limited circulation, being confined to certain continents or specific regions of the world (e.g., tick-borne encephalitis virus [TBEV] circulates in Europe and parts of Asia). However, recent globalization and the spread of competent arbovirus vectors have contributed to the introduction of these viruses in regions of the world where historically they never circulated (e.g., WNV, ZIKV, and CHIKV in the Americas). Environmental factors have also contributed to expansion of arboviruses under conditions which have favored the vector, the virus, or both. Introductions of new arboviruses or their emergence into a new region or continent has become common with the ease of travel and movement of people, animals, and vectors. Also, changes in the vector ecology or number of susceptible hosts in a population plays an important role in arbovirus transmission, particularly where humans are the primary amplifying host. Worldwide globalization has been implicated as the major cause of the introduction of new vectors into regions. This includes increases in travel of infected humans, animals, or vectors, providing a unique environment in which the pathogen adapts and thrives due to the abundance of susceptible hosts (<link linkend="ch0117s0009s0002li0022">22</link>). For example, WNV, which commonly circulates in East Africa and in the Middle East, was detected and isolated in 1999 in North America. Genetic analysis suggested that the emergence of WNV in the Americas was due to importation of WNV from the Middle East. The method of introduction by either mosquitoes or hosts was not fully determined. Nevertheless, WNV moved across the United States at an alarming speed following its emergence in 1999 in New York. This was due to the increased virus susceptibility of the New World avian amplifying hosts in comparison to the Old World avian host. Hence, the epizootic transmission of WNV in North America caused an alarming number of avian deaths, particularly among corvids, most frequently the American crow (<emphasis>Corvus brachyrhynchos</emphasis>) (<link linkend="ch0117s0009s0002li0023">23</link>). Another example of a rapid geographical expansion of an arbovirus is the transmission of CHIKV primarily by the vector, <emphasis>Aedes aegypti.</emphasis> A single point mutation in the membrane fusion glycoprotein of CHIKV ECSA lineage viruses increased its adaptation to <emphasis>Aedes albopictus</emphasis> and led to large outbreaks in tropical areas of the Indian Ocean (<link linkend="ch0117s0009s0002li0024">24</link>, <link linkend="ch0117s0009s0002li0025">25</link>). Later, in 2014, Asian-genotype CHIKV emerged in the Americas, where it was introduced in the small island of St. Martin in the Caribbean. Within 1 year of CHIKV introduction in the Caribbean, the virus had expanded into 26 Caribbean islands and 14 countries, with over 1 million reported cases (reported by the Pan American Health Organization [PAHO]). Although CHIKV has a sylvatic cycle, its transmission is primarily from human to mosquito to human; thus, its expansion into the Americas was believed to be through an infected human traveling from an Asian region of endemicity to the Americas. Sequence analysis determined that the circulating virus was of the Asian genotype (<link linkend="ch0117s0009s0002li0026">26</link>). Following the chikungunya outbreak, another historical event in arbovirus geographical expansion occurred. The first autochthonous transmission of ZIKV in the Americas was reported in March 2014 in the Easter Island of Chile, and then the virus emerged in Brazil in March of 2015 (<link linkend="ch0117s0009s0002li0027">27</link>). Previously, ZIKV was thought to circulate mostly in Asia and East Africa regions, causing mild disease with no known outbreaks (<link linkend="ch0117s0009s0002li0028">28</link>). In the early 2000s, this virus had been expanding in regions of the South Pacific, with the first large outbreak reported in the Federated States of Micronesia island of Yap in 2007 (<link linkend="ch0117s0009s0002li0029">29</link>). Following its 2015 introduction in Brazil, ZIKV rapidly expanded throughout the Americas and the Caribbean islands, such that within 1 year it had been reported in 11 countries (PAHO website: <ulink url="http://www.paho.org/hq/index.php?option=com_content%26view=article%26id=11959:timeline-of-emergence-of-zika-virus-in-the-americas%26Itemid=41711%26lang=en">http://www.paho.org/hq/index.php?option=com_content&amp;view=article&amp;id=11959:timeline-of-emergence-of-zika-virus-in-the-americas&amp;Itemid=41711&amp;lang=en</ulink>). Previous reports indicated that ZIKV caused a self-limiting mild disease consisting of fever, rash, myalgia, and conjunctivitis (<link linkend="ch0117s0009s0002li0029">29</link>); thus, its introduction into the Americas would have not caused high morbidity or mortality in the affected population. However, its association with cases of the congenital birth defect microcephaly reported in newborns infected <emphasis>in utero</emphasis> by ZIKV-infected women in Brazil caused a public health emergency and mobilization of global public health agencies (e.g., the World Health Organization [WHO]) (<link linkend="ch0117s0009s0002li0030">30</link>).</para>
        <beginpage/>
        <para id="ch0117s0001s0003p0005">Although the introduction and spread of arboviruses into new regions of the world are alarming, the resurgence of known viruses and the discovery of new viruses are just as important. For example, there have been increasing reports of newly identified cases in the United States of disease caused by Powassan virus, a tick-borne virus discovered in Powassan, Ontario, Canada, in 1958. Climate change favoring the vector abundance has been implicated as the main cause of the detection of these new cases. A vaccine-preventable disease, YF reemerged in Africa and South America in 2016, causing large outbreaks, with a total of 7,509 suspected cases and 171 deaths reported from six different countries (<link linkend="ch0117s0009s0002li0031">31</link>). This could be due to a shortage in vaccine availability as well as a lack of routine vaccination in countries where the vector and virus are endemic and circulate, especially areas that have the capacity to maintain a sylvatic cycle. Other new viruses have been discovered recently, including Heartland virus (genus <emphasis>Bandavirus</emphasis>), the agent of severe fever with thrombocytopenia syndrome (genus <emphasis>Bandavirus</emphasis>), and Bourbon virus (genus <emphasis>Thogotovirus</emphasis>) (<link linkend="ch0117s0009s0002li0032">32</link>–<link linkend="ch0117s0009s0002li0034">34</link>), all of which are transmitted by ticks (<link linkend="ch0117s0009s0002li0035">35</link>–<link linkend="ch0117s0009s0002li0039">39</link>). These viruses have caused severe disease and mortality in humans, and there is still much to learn about their natural host and transmission cycle. The most current information on transmission of medically important arboviruses worldwide is available on the Centers for Disease Control and Prevention (CDC) and WHO websites (<ulink url="https://www.cdc.gov/ncezid/dvbd/about.html">https://www.cdc.gov/ncezid/dvbd/about.html</ulink> and <ulink url="http://www.who.int">www.who.int</ulink>, listed by disease).</para>
      </sect2>
      <sect2 id="ch0117s0001s0004">
        <title>CLINICAL SIGNIFICANCE</title>
        <anchor id="ch0117s0001s0004a0001"/>
        <anchor id="ch0117s0001s0004a0002"/>
        <para id="ch0117s0001s0004p0001">Natural infection with an arbovirus occurs when an infected arthropod takes a blood meal from a susceptible person; however, other modes of infection are possible. Many illnesses caused by medically important arboviruses that are human pathogens display broad clinical presentations ranging from mild flu-like symptoms, such as fever, malaise, rash, and headache, to severe disease, with hemorrhage and encephalitis occasionally leading to death. These clinical symptoms can be categorized according to whether the virus is primarily either viscerotropic or neurotropic. Viscerotropic viruses cause febrile illnesses that often present with rash and arthralgia. Additional reported clinical symptoms include myalgia, jaundice, respiratory symptoms, photophobia, and others. A summary of viral tropism and associated complications resulting from severe disease in humans for the commonly reported arboviruses is presented in<link linkend="ch0117s0001s0002a0007">Table 1</link>. Although most published reports often focus on severe cases, mild forms of disease can cause significant morbidity and sequelae. For example, persons with dengue fever (a mild form of the disease) may be absent from work or school for 7 days or more, with occasional sequelae of fatigue and general malaise that can last for months (<link linkend="ch0117s0009s0002li0040">40</link>). In more extreme situations, permanent irreversible damage is caused by some arbovirus infections. For example, CHIKV can cause severe arthralgia and loss of function of hands and feet, which may be irreversible (<link linkend="ch0117s0009s0002li0041">41</link>). Severe WN disease can manifest with poliomyelitis-like neurological symptoms, including flaccid paralysis, which may lead to permanent damage to the nervous system (<link linkend="ch0117s0009s0002li0042">42</link>). Similar to poliovirus infection, neurons in the anterior horn of the spinal cord are also vulnerable to WNV. Lastly, as many as 1 of 10 women who have been infected with ZIKV during their pregnancy could give birth to a baby with congenital defects and particular neurological abnormalities, including microcephaly (<link linkend="ch0117s0009s0002li0043">43</link>); however, other estimates have estimated the rate of microcephaly at approximately 1% (<link linkend="ch0117s0009s0002li0044">44</link>). Zika virus also causes severe neurological symptoms in adults similar to Guillain-Barré syndrome (<link linkend="ch0117s0009s0002li0045">45</link>).</para>
        <para id="ch0117s0001s0004p0002">Commonly observed clinical symptoms for neurotropic arboviruses include coma, meningitis, flaccid paralysis, encephalitis, microcephaly, and Guillain-Barré syndrome. Neurotropic arboviruses include the genera<emphasis>Flavivirus</emphasis> (JEV and TBEV subcomplex), <emphasis>Alphavirus</emphasis> (VEEV, EEEV, and WEEV), and <emphasis>Orthobunyavirus</emphasis> (LACV and Jamestown Canyon virus [JCV]) and <emphasis>Phlebovirus</emphasis> (Toscana virus [TOSV]). Neuropathogenesis includes two important yet distinct factors: neuroinvasiveness and neurovirulence. Neuroinvasiveness is the capacity of the virus to invade the central nervous system (CNS) and/or the peripheral nervous system (PNS). Neurovirulence is defined as the replication of the virus within neuron or glial cells in the CNS and/or PNS. JEV and TBEV serocomplex flaviviruses have adapted to replicate in the nervous system. Although many nonneurotropic arboviruses are reported to have caused cases of encephalitis, these viruses are not neurotropic, and the reported encephalitis is often observed during multiorgan failure associated with fatal cases (<link linkend="ch0117s0001s0002a0007">Table 1</link>). The envelope glycoprotein is an important determinant for flaviviral neurotropism and linked to the glycosylation variants of the envelope gene product. The most important host risk factors for severe flavivirus infection are age, genetics, immunocompromised status, and preexisting flavivirus immunity. Most flavivirus infections cause either an asymptomatic or inapparent infection. The rate of neuroinvasive disease is ≤0.1% but varies with the prevalence of the virus in the population. For example, in 2002, during the peak of WNV transmission in the United States, the rate of neuroinvasive disease was 1 in every 150 infections, with a mortality rate of 5 to 10% (<link linkend="ch0117s0009s0002li0046">46</link>, <link linkend="ch0117s0009s0002li0047">47</link>). In nonepidemic years, rates of neuroinvasive disease decreased; however, 2012 was an epidemic year, with rates of neuroinvasive disease comparable to those observed in the 2002 U.S. epidemic (<link linkend="ch0117s0009s0002li0048">48</link>).</para>
        <para id="ch0117s0001s0004p0003">Age is the most common host risk factor documented in both human clinical studies and animal models. Younger individuals have a higher susceptibility to neuroinvasive disease, implying that the developing nervous system is more susceptible to the virus. For example, encephalitis and severe disease in JEV infections are primarily observed in children from 0 to 9 years old. For WNV, neuroinvasive disease increases with age. Younger adults have a higher risk of aseptic meningitis, whereas elderly patients have a higher risk of encephalitis with poor outcome. For the elderly, the risk of neuroinvasive disease is most likely related to a compromised immune system or preexisting medical conditions. Preexisting systemic conditions such as autoimmune diseases, diabetes, and obesity are some of the risk factors associated with WN and dengue severe disease (<link linkend="ch0117s0009s0002li0049">49</link>, <link linkend="ch0117s0009s0002li0050">50</link>). These conditions, which result in a less functional and responsive immune system, are also associated with the reduction in vaccine responsiveness in elderly individuals.</para>
        <anchor id="ch0117s0001s0004a0003"/>
        <beginpage pagenum="1900"/>
        <para id="ch0117s0001s0004p0004"><emphasis>In utero</emphasis> transmission has been poorly studied for most arboviruses; however, the 2015 Zika outbreak in the Americas prompted the first studies that carefully documented <emphasis>in utero</emphasis> transmission of an arbovirus (reviewed in reference <link linkend="ch0117s0009s0002li0051">51</link>). Cohort studies that monitored pregnant women infected with ZIKV at various stages of their pregnancy documented the infants’ developmental abnormalities with specific neurological outcomes. These studies indicated that the fetuses or infants had severe cerebral atrophy, ventriculomegaly, and intracranial calcification, seen in <emphasis>in utero</emphasis> ultrasound images and after delivery. Although most of the focus has been on the development of microcephaly, there is a wide spectrum of developmental malformations associated with exposure to ZIKV <emphasis>in utero</emphasis>, referred to as congenital Zika syndrome (CZS). There are five categories of CZS, including neurological, musculoskeletal, ocular, genitourinary, and others that could not be grouped into specific categories (reviewed in reference <link linkend="ch0117s0009s0002li0052">52</link>). Other studies have also shown transmission of DENV and WNV from the infected mother to the fetus (transplacental transmission); however, there were no serious outcomes following birth (<link linkend="ch0117s0009s0002li0053">53</link>, <link linkend="ch0117s0009s0002li0054">54</link>).</para>
        <para id="ch0117s0001s0004p0005">Viscerotropic arboviruses include but are not limited to DENV, YFV, and Rift Valley fever virus (RVFV) (<link linkend="ch0117s0001s0002a0007">Table 1</link>). Common clinical symptoms for these viruses are fever, malaise, headache, photophobia, and occasionally rash and arthralgia. Other symptoms include hepatitis and jaundice, which is sometimes misdiagnosed as hepatitis viral infection. A distinct clinical manifestation for these viruses is hemorrhage and shock syndrome. A relatively small percentage (1 to 5%) of symptomatic patients develop hemorrhage during the course of illness, and of those, 0.5 to 5% progress to multiorgan failure and eventually death (<link linkend="ch0117s0009s0002li0055">55</link>). Disease caused by other viruses that present with viral hemorrhagic syndrome, such as Lassa virus (arenavirus), Ebola virus, and Marburg virus (filoviruses), can be misdiagnosed as hemorrhagic arbovirus syndromes. However, there are sufficient clinical differences between arboviral and other hemorrhagic viral infections, as well as geographical constraints, to facilitate proper clinical diagnosis.</para>
        <para id="ch0117s0001s0004p0006">Since there are few pathognomonic symptoms associated with each arbovirus, there is often misdiagnosis due to nonspecific clinical symptoms during the early acute stage of an infection. Other diseases for which prophylaxis is available or which are vaccine preventable, such as rubella/measles, influenza, leptospirosis, and malaria, have been misdiagnosed as arboviral infections. Clinical misdiagnosis delays appropriate medical treatment and triage of patients. Common misdiagnoses for viscerotropic arboviruses are malaria and leptospirosis. Suspected malaria-infected patients were often treated with antimalaria prophylaxis prior to laboratory confirmation of<emphasis>Plasmodium</emphasis> infection. There is no known negative impact of malaria treatment for patients infected with an arbovirus; however, there are no studies to support this observation (<link linkend="ch0117s0009s0002li0056">56</link>). Encephalitis and hemorrhagic symptoms associated with certain arbovirus infections can aid an accurate clinical diagnosis.</para>
        <para id="ch0117s0001s0004p0007">Vaccines and antiviral medications for prophylaxis or treatment are limited for most arboviruses (<link linkend="ch0117s0001s0002a0007">Table 1</link>). Clinicians principally rely on supportive care, including fluid replacement, analgesics, and transfusion of blood products. When making a diagnosis of arbovirus infection, the clinician should always consider the geographical location where the infection was acquired. Patient information such as vaccine history, travel history, and exposure to vectors should also be considered. While many arboviruses circulate in specific geographical regions, other arboviruses, such as DENV, now circulate in most tropical and subtropical regions of the world due to their rapid geographical expansion. By using known incubation periods, risk of infection by geographical distribution of the virus, and presence of a competent vector, clinical diagnosis can be considerably narrowed. Concurrent infections with either cocirculating arboviruses or other infectious or parasitic diseases (e.g., leptospirosis, influenza, and malaria) can occur (<link linkend="ch0117s0009s0002li0057">57</link>–<link linkend="ch0117s0009s0002li0059">59</link>). There is no clear evidence that concurrent infections have higher morbidity or mortality rates, because the small sample size prohibits studies with sufficient statistical power.</para>
      </sect2>
      <sect2 id="ch0117s0001s0005">
        <title>COLLECTION, TRANSPORT, AND STORAGE OF SPECIMENS</title>
        <anchor id="ch0117s0001s0005a0001"/>
        <anchor id="ch0117s0001s0005a0002"/>
        <para id="ch0117s0001s0005p0001">Serum is the most commonly collected specimen for arbovirus diagnostics; however, other specimens obtained from an acute suspected arbovirus infection in humans may include whole blood, plasma, urine, semen, tissues, and saliva, with varying utility. Viscerotropic arboviruses can be detected in sera of infected patients during the first 120 h (5 days) following symptom or fever onset (<anchor id="ch0117s0001s0005a0003"/><link linkend="ch0117s0001s0005a0006">Fig. 2</link>); however, the duration of viral RNA detection (days postonset [DPO]) depends on the specimen type and analytical sensitivity of the test being performed (<link linkend="ch0117s0009s0002li0060">60</link>). Nucleic acid amplification tests (NAAT) are the most specific and often the most sensitive tests for case confirmation, although for neurotropic viruses, detection of viral nucleic acid in blood is often difficult. Serum specimens are collected in red-top or tiger-top serum separator Vacutainer collection tubes, while whole blood is collected in EDTA-treated Vacutainer blood collection tubes. Other modes of blood collection include obtaining dried blood spots; however, limited studies have validated this technique (<link linkend="ch0117s0009s0002li0061">61</link>, <link linkend="ch0117s0009s0002li0062">62</link>). To preserve the nucleic acid integrity, specimens collected during the viremic phase (0 to 5 DPO) should be stored at −80°C. Freeze-thawing of these specimens usually degrades the viral RNA rather quickly and can significantly reduce viral titers, i.e., by as much as 1 log, following a single freeze-thaw cycle. Because humans are the primary amplifying host for several viruses, such as DENV, CHIKV, or YFV, titers of these viruses in blood and tissue are ~10<superscript>3</superscript> to 10<superscript>9</superscript> genome equivalent copies/ml and are readily detected by most molecular diagnostic tests. For neurotropic arboviruses, such as WNV, St. Louis encephalitis virus, and JEV, there exists an intermediate (avian or swine) host; thus, humans are dead-end incidental hosts. For these viruses, identification in blood is less likely due to low viral titers (~10 to 1,000 PFU/ml), which may be below the limit of detection (LOD) of many reverse transcription-PCR (RT-PCR) tests (<link linkend="ch0117s0009s0002li0063">63</link>). For patients clinically diagnosed with encephalitis or meningitis, a cerebrospinal fluid (CSF) specimen should be tested for the presence of virus-specific antibodies (IgM) (<link linkend="ch0117s0009s0002li0064">64</link>) (<link linkend="ch0117s0001s0005a0006">Fig. 2</link>). However, depending on the immune status of the patient or timing of specimen collection, viral nucleic acid can be detected in CSF by RT-PCR or virus isolation in culture. The sensitivities of these diagnostic tests depend on the infecting virus and the time frame of specimen collection. For cases that are captured prior to neuroinvasion or the onset of encephalitic symptoms, a blood specimen is more likely to yield a positive result than CSF. Recent improvements in PCR technology have shifted the LOD for many of these NAATs so as to detect arboviruses at much lower virus titers. A few studies have shown arboviral persistence, where virus shedding is detected for longer periods of time, such as weeks or months. Studies have reported virus persistence, particularly for WNV (<link linkend="ch0117s0009s0002li0065">65</link>), Colorado tick fever virus (<link linkend="ch0117s0009s0002li0066">66</link>, <link linkend="ch0117s0009s0002li0067">67</link>), and ZIKV. For ZIKV, this viral persistence varied by specimen type, as virus was detected in semen and urine for weeks to months, indicating persistence in tissues such as testes, prostate, and kidney (<link linkend="ch0117s0009s0002li0068">68</link>, <link linkend="ch0117s0009s0002li0069">69</link>).</para>
        <anchor id="ch0117s0001s0005a0004"/>
        <beginpage pagenum="1901"/>
        <figure id="ch0117s0001s0005f0001"><title><anchor id="ch0117s0001s0005a0005"/><phrase role="figureLabel"><anchor id="ch0117s0001s0005a0006"/><link linkend="ch0117s0001s0005a0003">FIGURE 2</link></phrase> Time periods in which different sample analytes (RNA [orange], IgM [green], and IgG [purple] antibodies) would be assayed for arboviral diagnoses in relation to the time of symptom onset. The y axis represents the probability of detection over time (<emphasis>x</emphasis> axis).
</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0117f06.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <para id="ch0117s0001s0005p0002">Serum specimens tested for immunodiagnostic tests should be collected during both the acute phase (0 to 5 DPO) and convalescent phase (6 to 14 DPO). Paired specimens provide the highest likelihood of a test result being confirmed by seroconversion by detection of IgM or IgG. For CSF specimens obtained from patients suspected of having a neurotropic arboviral infection, IgM antibodies can be detected earlier in the course of infection in CSF than in sera; however, both specimens (serum and CSF) should be obtained for best results. A single IgM-positive serum specimen provides a suspect diagnosis of a recent arbovirus infection; however, serological cross-reactivity necessitates neutralization testing for confirmation, and timing of acute infection cannot be determined due to persistence of the IgM response for some arboviruses (e.g., WNV and ZIKV) (<anchor id="ch0117s0001s0005a0007"/><link linkend="ch0117s0001s0005a0010">Fig. 3</link>) (<link linkend="ch0117s0009s0002li0070">70</link>). However, a single IgM-positive CSF specimen is suggestive of an acute arbovirus infection.</para>
        <para id="ch0117s0001s0005p0003">Tissue specimens are collected for direct detection methods from autopsies in fatal cases and occasionally from antemortem biopsies. Relevant tissue types vary, depending on the suspected virus, but may include brain, heart, kidney, liver, lymphoid and hematopoietic tissues, and placenta. Other specimens collected for diagnostic testing include arthropods, such as ticks, mosquitoes, sand flies, and midges. These specimens are used for virus isolation and/or tested for the presence of viral nucleic acids. Arthropod field tests for virus identification in the vector include rapid tests such as a dipstick test using antibodies directed against a viral antigen (e.g., envelope glycoprotein). These tests are commercially available for WNV, DENV, EEEV, and RVFV (<link linkend="ch0117s0009s0002li0071">71</link>–<link linkend="ch0117s0009s0002li0073">73</link>).</para>
        <para id="ch0117s0001s0005p0004">Ideally, transport of specimens should be rapid, and samples other than for pathologic evaluation should be frozen and maintained on dry ice. In situations where receipt of specimens is likely to occur within 24 h of collection, it is best to maintain the specimen at 4°C to avoid a freeze-thaw cycle, and testing should be done immediately upon arrival at the laboratory. Pathology samples should be fixed in 10% neutral buffered formalin at room temperature and then transferred to 70% ethanol, if processing will be delayed more than 2 weeks, to prevent antigen cross-linking and nucleic acid degradation. Samples for electron microscopy should be fixed in 2.5% glutaraldehyde, held in phosphate buffer, and shipped on wet ice (<link linkend="ch0117s0009s0002li0074">74</link>, <link linkend="ch0117s0009s0002li0075">75</link>). Due to the potential infectious nature of fresh samples, especially for positive-sense RNA viruses, transport of confirmed nonfixed samples or isolates to the lab should ideally follow International Air Transport Association regulations, which require a triple-packaging method; however, samples from suspected cases can be packaged with the same procedures as any routine diagnostic specimen. Proper personal protective equipment should be used, and specimens should be handled in a biosafety level 2 (BSL2) or BSL3 lab, as specified by the Biosafety and Microbial and Biomedical Laboratories manual (BMBL) (6th edition [<ulink url="https://www.cdc.gov/labs/BMBL.html">https://www.cdc.gov/labs/BMBL.html</ulink>]), and safely manipulated in a type II biological safety cabinet. Specimens that are heat inactivated at 57°C or inactivated via lysis buffer are typically safe to handle outside a biological safety cabinet. Once the specimens are tested, long-term storage should be at −80°C for an indefinite period. For specimens that are virus positive or immune positive, −20°C is best for long-term storage, i.e., up to 20 years. Formalin-fixed specimens can be stored long-term in 70% ethanol or in paraffin blocks after having been processed for histology.</para>
        <anchor id="ch0117s0001s0005a0008"/>
        <beginpage pagenum="1902"/>
        <figure id="ch0117s0001s0005f0002"><title><anchor id="ch0117s0001s0005a0009"/><phrase role="figureLabel"><anchor id="ch0117s0001s0005a0010"/><link linkend="ch0117s0001s0005a0007">FIGURE 3</link></phrase> Optimal laboratory testing algorithm for human serum specimens for a suspected arbovirus infection. For patients with neuroinvasive disease, IgM is often detectable in CSF when the patient presents with neurological symptoms, and PCR may be negative. The methods depicted may be available only in specialized arbovirus reference laboratories.
</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0117f07.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
      </sect2>
      <sect2 id="ch0117s0001s0006">
        <title>DIRECT DETECTION</title>
        <anchor id="ch0117s0001s0006a0001"/>
        <anchor id="ch0117s0001s0006a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0117s0002">
      <title>Pathological Specimens and Microscopy</title>
      <anchor id="ch0117s0002a0001"/>
      <anchor id="ch0117s0002a0002"/>
      <para id="ch0117s0002p0001">Arboviral infections, particularly those involving the CNS, can cause characteristic histopathologic changes; however, there are no specific morphologic features (e.g., viral inclusions) to distinguish the specific viral etiology. Viral identification via immunohistochemistry or<emphasis>in situ</emphasis> hybridization testing can be performed on formalin-fixed paraffin-embedded (FFPE) biopsy or postmortem tissue specimens. Electron microscopy can be performed on glutaraldehyde (preferred) or formalin-fixed tissues. These assays afford the ability to not only determine presence of virus in a tissue but also to localize virus within specific compartments or cell types within the tissue, potentially providing insights into pathogenesis. Because autopsies are not practiced and/or culturally accepted in some regions of the world where arboviruses circulate, pathology studies for arbovirus-related fatalities are relatively few. The most complete pathology information from fatal cases is primarily from flavivirus-related deaths (JEV, WNV, YFV, and DENV). Optimal tissue sampling and testing are determined by viral tropism and vary by arbovirus family and species. For neurotropic viruses that infect the CNS, tissue specimens are collected and tested for the presence of viral antigens or nucleic acid by immunohistochemistry or <emphasis>in situ</emphasis> hybridization, respectively; regions of the CNS tested include the cortex, cerebellum, and brainstem. For JEV and other neurotropic arboviruses (WNV, EEEV, St. Louis encephalitis virus [SLEV], LACV, etc.), autopsy brain tissues are primarily tested with NAAT and cell culture virus isolation or FFPE specimen-based techniques for confirmation (<link linkend="ch0117s0009s0002li0076">76</link>, <link linkend="ch0117s0009s0002li0077">77</link>). For viscerotropic viruses, such as DENV and YFV, other organs, such as liver, kidney, lung, lymph nodes, spleen, and heart, are considered for testing (<link linkend="ch0117s0009s0002li0078">78</link>, <link linkend="ch0117s0009s0002li0079">79</link>). Formalin-fixed paraffin-embedded tissues can also be subjected to RT-PCR techniques for detection of viral genome in tissue specimens (<link linkend="ch0117s0009s0002li0080">80</link>, <link linkend="ch0117s0009s0002li0081">81</link>).</para>
    </sect1>
    <sect1 id="ch0117s0003">
      <title>Antigen Detection (Nonimmunohistochemistry)</title>
      <anchor id="ch0117s0003a0001"/>
      <anchor id="ch0117s0003a0002"/>
      <para id="ch0117s0003p0001">Viral antigen detection tests have been developed as field tests for rapid identification of viruses in arthropod specimens by targeting the structural proteins (<link linkend="ch0117s0009s0002li0073">73</link>, <link linkend="ch0117s0009s0002li0082">82</link>, <link linkend="ch0117s0009s0002li0083">83</link>). Any arthropod specimens that were positive in a rapid diagnostic test were then confirmed by either RT-PCR or virus isolation. Enzyme-linked immunosorbent assays (ELISAs) for viruses such as RVFV and EEEV have been developed for use with mosquito specimens (<link linkend="ch0117s0009s0002li0084">84</link>, <link linkend="ch0117s0009s0002li0085">85</link>). Other antigen tests were developed to detect the nonstructural protein 1 (NS1) antigen of DENV and ZIKV in human sera. The flavivirus NS1 glycoprotein produces a humoral response and is known as a complement-fixing antigen. NS1 is essential for viral replication and is secreted as a hexamer composed of three dimer subunits which is readily detected by ELISA. NS1 tests were developed in a microplate ELISA format for both human and mosquito specimens. Due to their ease of use compared to RT-PCR, these tests have been widely used for diagnostic purposes. Rapid NS1 antigen tests have demonstrated specificity for detecting acute arboviral infections due to a lesser degree of antigenic cross-reactivity between flaviviral NS1 proteins; however, detection of NS1 has been demonstrated to be less sensitive than similar assays using structural protein analytes (<link linkend="ch0117s0009s0002li0086">86</link>, <link linkend="ch0117s0009s0002li0087">87</link>).</para>
      <para id="ch0117s0003p0002">The DENV NS1 ELISA can be implemented in many resource-poor countries for virus surveillance. The sensitivity of the first DENV NS1 antigen capture ELISA ranged from 1 to 4 ng/ml; however, commercial tests have sensitivities of 50 ng/ml of serum (<link linkend="ch0117s0009s0002li0088">88</link>–<link linkend="ch0117s0009s0002li0090">90</link>). Results from earlier studies suggested that NS1 levels in blood correlated with disease severity among DENV patients, although these results were not corroborated by later studies (<link linkend="ch0117s0009s0002li0089">89</link>, <link linkend="ch0117s0009s0002li0090">90</link>). DENV NS1 studies suggest that antibodies against DENV NS1 bind to capillary endothelial cells and are responsible for capillary leakage (<link linkend="ch0117s0009s0002li0091">91</link>). The NS1 glycoprotein has DENV serotype-specific epitopes capable of distinguishing between DENV serotypes in an ELISA (<link linkend="ch0117s0009s0002li0092">92</link>). However, the NS1 antigen test is less sensitive in secondary DENV infections due to immune complexes formed from multiple DENV exposures (<link linkend="ch0117s0009s0002li0093">93</link>). The NS1 test is commercially available for DENV, and many investigators have evaluated its sensitivity (60 to 75%) and specificity (71 to 80%) (<link linkend="ch0117s0009s0002li0094">94</link>–<link linkend="ch0117s0009s0002li0097">97</link>). Because the specificity of the NS1 test is higher than that of the IgM tests, it may also be useful in differentiating between flaviviruses. However, viruses in the JEV serocomplex group do not develop sufficiently high viral titers, in contrast to what has been observed in DENV infections; therefore, it is unlikely that an NS1 antigen detection test for flaviviruses in the JEV serocomplex will be used for diagnostics.</para>
      <anchor id="ch0117s0003a0003"/>
      <beginpage pagenum="1903"/>
      <para id="ch0117s0003p0003">NS1 antigen detection has been used to detect ZIKV. Homology of ZIKV NS1 to NS1 of other flaviviruses allows differentiation between ZIKV and other flaviviruses, such as DENV. The ZIKV NS1 ELISA has demonstrated sensitivities of 31.6 and 85.7% for specimens obtained from regions where the virus is nonendemic and endemic, respectively (<link linkend="ch0117s0009s0002li0098">98</link>). Serum specimens are collected during the viremic phase of the infection to optimize the window of detection where the highest titer of the protein is found.</para>
    </sect1>
    <sect1 id="ch0117s0004">
      <title>Nucleic Acid Detection</title>
      <anchor id="ch0117s0004a0001"/>
      <anchor id="ch0117s0004a0002"/>
      <para id="ch0117s0004p0001">There are various NAAT methods to detect arbovirus nucleic acid, including conventional and real-time RT-PCR (rRT-PCR), nested PCR, reverse transcription loop-mediated isothermal amplification (RT-LAMP), SYBR green I testing, and use of the TaqMan array. The sensitivity of any NAAT is dependent on the efficiency of the extraction and purification of the target RNA template. Commercial assays for extraction are an improvement over phenol-chloroform extraction techniques, which produced inconsistent results because of RNA degradation during the purification process. The newer commercial assays are often faster and more reliable and provide RNA stabilization to avoid loss of target RNA. The only disadvantage of NAAT is the potential for contamination with target analyte or amplicons; however, separating template-free or clean labs from nucleic acid amplification labs can eliminate potential contamination. Results of NAAT confirm the identity of the infecting virus with a rapid turnaround. However, these assays are not necessarily available in clinical laboratories and are often found in specialized laboratories, such as CDC, regional reference, and academic laboratories.</para>
      <sect2 id="ch0117s0004s0001">
        <title>RT-PCR</title>
        <anchor id="ch0117s0004s0001a0001"/>
        <anchor id="ch0117s0004s0001a0002"/>
        <para id="ch0117s0004s0001p0001">Conventional RT-PCR uses gel electrophoresis, where the molecular sizes (in kilobases) of DNA fragments generated from test samples are compared to those of the amplified DNA fragments of known viral standards. This test cannot be used for nucleic acid quantification, since gel electrophoresis uses ethidium bromide as a method of detection and the sensitivity is dependent on the LOD (1 to 5 ng of nucleic acid) of ethidium bromide. The most sensitive test using conventional RT-PCR is the nested RT-PCR. DENV nested RT-PCR has been shown to have sensitivity almost equivalent to that of rRT-PCR and in some cases better sensitivity when compared according to DENV serotype (<link linkend="ch0117s0009s0002li0099">99</link>). Positive results from nested PCR techniques should be confirmed, given the propensity for amplification of contaminating nucleic acids.</para>
        <para id="ch0117s0004s0001p0002">rRT-PCR with fluorescently labeled probes has become a routine technique in some laboratories. This is due to its simple format (tubes are not opened after amplification, decreasing the risk of contamination), generally high sensitivity, multiplex capacity, and ability to quantify viral titers. Primers and fluorescent probes are designed to target the conserved regions of the genome for the most specific result. Only when there is uncertainty of the specificity of the primers should a second set of primers and/or sequencing be applied to verify RT-PCR results; however, these additional tests are not required (<link linkend="ch0117s0001s0005a0010">Fig. 3</link>). Some tests are designed to detect any virus within a particular genus using consensus sequences (e.g., <emphasis>Flavivirus, Alphavirus</emphasis>, and <emphasis>Orthobunyavirus</emphasis>); these tests are referred to as “pan” or “universal” format tests (<link linkend="ch0117s0009s0002li0100">100</link>–<link linkend="ch0117s0009s0002li0102">102</link>). Universal primers are useful for detecting agents of emerging infectious diseases where an arbovirus is the suspected pathogen. Once the genus of the unknown virus is determined, specific primers for each species within that genus are then used to identify and confirm the infecting pathogen. The fluorescence is measured and captured as cycle threshold (<emphasis>C</emphasis><subscript><emphasis>T</emphasis></subscript>) values, which are often correlated to either genome equivalent copies or PFU; these values can be determined with a standard curve to extrapolate viral load in the specimen.</para>
        <para id="ch0117s0004s0001p0003">The recent need for multiplex arbovirus testing has caused researchers to rely on assays that detect DENV (multiplex by serotype), the combination of CHIKV and DENV, or CHIKV, DENV, and ZIKV in a single rRT-PCR (<link linkend="ch0117s0009s0002li0102">102</link>, <link linkend="ch0117s0009s0002li0103">103</link>). These multiplex assays are particularly helpful in regions where multiple arboviruses circulate and for dengue virus, for which multiple serotypes circulate and physicians are unable to clinically differentiate the infecting pathogen. The only disadvantage with these multiplex assays is that they tend to have lower sensitivities than singleplex formats. Another method of detecting multiple viral targets in singleplex reactions is the use of TaqMan array cards (TAC). As many as 40 pathogens are detected in one card, and multiple arboviruses can be spotted in singleplex rRT-PCR format. Through the use of microfluidics, the specimen migrates into individual wells that have lyophilized primers and probes corresponding to each target pathogen. Due to the lower volume of specimen used in each TAC, the test is less sensitive than most rRT-PCRs or even multiplex rRT-PCRs. The main advantage of this technology is the ability to test for many pathogens with similar etiology in one test (<link linkend="ch0117s0009s0002li0104">104</link>). The BioFire global fever panel (GF panel) has been designed as a multiplex assay platform to detect nucleic acids from a variety of human pathogens that result in acute febrile illness in a contained and automated system array for which arboviruses (CHIKV and DENV) can be detected in addition to malarial and leptospiral agents (<link linkend="ch0117s0009s0002li0105">105</link>).</para>
      </sect2>
      <sect2 id="ch0117s0004s0002">
        <title>RT-LAMP</title>
        <anchor id="ch0117s0004s0002a0001"/>
        <anchor id="ch0117s0004s0002a0002"/>
        <para id="ch0117s0004s0002p0001">The nucleic acid detection technique known as RT-LAMP was developed for various arboviruses. The assay requires only one standard temperature (64°C) and is considered a low-cost alternative to conventional and rRT-PCR, because it does not require thermal cycling. The reaction is a strand displacement reaction using four different primers that recognize six regions of the target gene using<emphasis>Bst</emphasis> polymerase instead of <emphasis>Taq</emphasis> polymerase. The amplified product can be visually identified either by a white precipitate or by SYBR green, yielding a green or yellow color change. This test has been developed for WNV, JEV, CHIKV, DENV, ZIKV, and RVFV (14, 106–109). A newly developed RT-LAMP using degenerative primers for YFV is highly sensitive; its sensitivity ranges from 83 to 100% during the first 4 days of acute infection, and it has a LOD of 19 PFU/ml (<link linkend="ch0117s0009s0002li0110">110</link>). The adaptation of the conventional RT-LAMP test using degenerative primers increased the sensitivity to be equivalent to or greater than that of many routine molecular diagnostics (e.g., RT-PCR [61.5%], RT-nested PCR [93.8%], quantitative RT-PCR [100%], and conventional RT-LAMP [63.1%]).</para>
        <anchor id="ch0117s0004s0002a0003"/>
        <beginpage pagenum="1904"/>
      </sect2>
    </sect1>
    <sect1 id="ch0117s0005">
      <title>Considerations for NAAT</title>
      <anchor id="ch0117s0005a0001"/>
      <anchor id="ch0117s0005a0002"/>
      <para id="ch0117s0005p0001">Diagnosis of arboviral infections with molecular techniques can encounter several challenges. Viscerotropic viruses such as DENV, CHIKV, and YFV can successfully be detected using NAAT techniques due to the development of higher and longer-lived viremias. Neurotropic viruses, however, are more routinely diagnosed via serological assays due to the low likelihood of virus being present in the periphery or cerebrospinal fluid when encephalitic symptoms occur. During a clinical study of JCV, CSF and serum specimens tested up to 3 days postonset were unable to be diagnosed via rRT-PCR (<link linkend="ch0117s0009s0002li0111">111</link>), which supports similar studies of WNV molecular testing (<link linkend="ch0117s0009s0002li0112">112</link>). These results highlight the limited utility of rRT-PCR diagnosis of neuroinvasive arboviruses in immunocompetent individuals.</para>
      <para id="ch0117s0005p0002">Although serological diagnosis of neuroinvasive arboviral infections remains the gold standard method, an increasing need for molecular testing in immunocompromised individuals has been recognized. Individuals on immunosuppressive therapies such as B cell depleting agents (e.g., rituximab), which inhibit the production of antibodies in recipients, are likely to test negative for serum or CSF antibodies to arboviruses. However, in documented cases, viral RNA was detected in serum, CSF, and tissues several months after onset of symptoms. Arboviral infections of WNV, Powassan virus [POWV], TBEV, EEEV, and JCV have been diagnosed through molecular testing in such circumstances (<link linkend="ch0117s0009s0002li0113">113</link>–<link linkend="ch0117s0009s0002li0117">117</link>).</para>
      <sect2 id="ch0117s0005s0001">
        <title>ISOLATION PROCEDURES</title>
        <anchor id="ch0117s0005s0001a0001"/>
        <anchor id="ch0117s0005s0001a0002"/>
        <para id="ch0117s0005s0001p0001">Arboviruses are generally isolated from serum specimens from infected humans and animals or from extracts from mosquitoes. Virus isolation serves as a confirmatory test for RT-PCR-positive specimens, helps to further characterize circulating strains for molecular epidemiology studies, and serves to identify novel or emerging arboviral agents (<link linkend="ch0117s0009s0002li0032">32</link>). Most arboviruses can be isolated from blood or tissue if the integrity of the specimen is maintained by appropriate handling and storage. These viruses require various degrees of biological containment (BSL2 or BSL3), and laboratories should consult the BMBL manual for proper biosafety practice. Low-passage-number viruses are preferred for phylogenetic analysis, since these viruses mutate at a rate of 1 × 10<superscript>−3</superscript> substitution/site/year. Interestingly, arboviruses’ mutation rates are 0.21 order of magnitude lower on average and their rates of synonymous substitutions are lower than those of all other RNA viruses (<link linkend="ch0117s0009s0002li0118">118</link>). Nevertheless, it is important to obtain viral isolates as reference material for future molecular characterization studies. Virus isolation can identify novel viruses, especially when an RT-PCR-positive sample cannot be categorized by a species-specific RT-PCR assay. For example, a specimen that is positive by universal primers in flavivirus NAAT but cannot be amplified in a flavivirus species-specific RT-PCR can then be isolated and sequenced to determine whether the virus is a new species within this family or genus.</para>
        <para id="ch0117s0005s0001p0002">Arbovirus isolation is performed in either primary cell culture or cell culture lines. Primary cultures typically include primary duck, chicken embryo, monkey, and hamster kidney cells. The common mammalian cell lines used for virus isolation include Vero, LLC-MK2, BHK-21, CER, SW13, and PK cells. Most infecting arboviruses cause characteristic cytopathic effects (CPE) (e.g., plaques, cell fusion, and/or syncytium formation). CPE patterns can assist in determining the genus and possibly the family of virus. Another viral amplification technique includes the intracerebral inoculation of specimen into the brains of 2- to 3-day-old suckling mice (SMB). If virus is present, the mouse will develop paralysis and die within 2 weeks of inoculation. Occasionally, viruses will require multiple passages in SMB for neuroadaptation of the viral isolate. Other organ specimens should also be harvested from infected mice, including liver and kidney. For example, certain orthobunyaviruses replicate at a higher titer in liver than in brain. Adaptation of the viral isolate in cell culture requires inoculation using homogenized infected tissue followed by multiple passages of the virus isolate in cell culture.</para>
        <para id="ch0117s0005s0001p0003">Many mosquito-borne arboviruses, including DENV and Sindbis virus, can also be amplified by direct injection into competent mosquitoes, such as<emphasis>Aedes, Culex</emphasis>, and <emphasis>Toxorynchites</emphasis> species (reviewed in reference <link linkend="ch0117s0009s0002li0119">119</link>), or in mosquito cell lines (C6/36 and AP61) (<link linkend="ch0117s0009s0002li0120">120</link>, <link linkend="ch0117s0009s0002li0121">121</link>). Occasionally, these viruses can cause persistent infections in mosquito cell lines with no apparent CPE. Careful quality control is required for maintenance of mosquito cell lines to monitor persistent infection by a virus contaminant.</para>
        <para id="ch0117s0005s0001p0004">When specimens are submitted for virus identification and isolation to a reference laboratory, multiple cell lines are used, depending on where the specimen is obtained and on known circulating viruses in the region. Typically, the specimen is first inoculated into a cell culture using at least one mosquito cell line (C6/36) and various mammalian cell lines, particularly Vero, LLC-MK2, and BHK-21. The inoculated cell culture flask is monitored daily for CPE, and a neutral pH is maintained in the cell culture flasks throughout the virus growth procedure. Acidic environments (pH &lt;6) cause conformational changes in the virus structural proteins, rendering the virus noninfectious. In the absence of CPE, a sample of the culture is tested with virus-specific PCR and/or for the presence of viral antigens using an immunofluorescent assay (IFA) that probes with cross-reactive monoclonal antibodies (MAbs) to identify viral family and/or genus. The virus isolate is stored in cell culture medium containing between 10 and 20% fetal bovine serum and at −80°C for future characterization studies. Currently, inoculation in SMB is not permitted in many labs due to Institutional Animal Care and Use Committee rules that prohibit this method of virus amplification. To isolate virus from human or animal serum, susceptible cells are inoculated with undiluted infected serum and two additional serum dilutions of 10<superscript>−1</superscript> and 10<superscript>−2</superscript> (to avoid viral interference for high-titer virus specimens). If a tissue specimen is received, it is homogenized and diluted on a weight-to-volume basis (10 to 20%).</para>
      </sect2>
      <sect2 id="ch0117s0005s0002">
        <title>IDENTIFICATION</title>
        <anchor id="ch0117s0005s0002a0001"/>
        <anchor id="ch0117s0005s0002a0002"/>
        <para id="ch0117s0005s0002p0001">IFA is used to identify the virus within infected cells (for either cell culture or tissue specimens) with virus-specific MAbs that target the structural gene products, since they are the most divergent yet conserved within species (<anchor id="ch0117s0005s0002a0003"/><link linkend="ch0117s0005s0002a0006">Fig. 4</link>). Antigenic characterization using species-specific MAbs cannot differentiate between genotypes or lineages and is useful only for viral species-specific identification. Polyclonal antibodies are also used to determine the virus family, followed by testing with species-specific MAbs. Some of the targeted MAbs cross-react with epitopes identified in all species within a family or genus of viruses. These broadly cross-reactive MAbs or polyclonal antibodies identify the family of virus, which can then be tested with specific MAbs that target epitopes within the structural proteins that are conserved between species. Some limitations of IFA are false-positive results due to background and nonspecific antibody reactivity. IFA is a subjective test and highly vulnerable to operator error. Depending on the tissue specimen, the background from the fluorescently tagged antibody can vary significantly. Autofluorescence can occur in certain specimens with high lipid content or an abundance of chitin (protein associated with insect exoskeleton). Immunohistochemistry performed on FFPE tissues has similar utility and constraints, with potential for cross-reactivity of antibodies among flaviviruses and other viruses and requires interpretation by experienced pathologists familiar with the specific assays. Use of IFA and IHC is most useful when coupled with molecular assays, since sequence analysis provides definitive differentiation between viruses within families and within serocomplex groups that determines the origin and the molecular epidemiology of the virus. Phylogenetic analysis can assist in tracking the virus movement and transmission within a region or throughout the world by spatial and temporal analyses (reviewed in reference <link linkend="ch0117s0009s0002li0122">122</link>). This analysis can determine the introduction rate of specific viruses in a region and the rate of evolution. Arbovirus evolution is interdependent on the host and the vector; thus, phylogenetic analysis cannot predict the dominant evolutionary change for increased adaptation to either host or vector (reviewed in reference <link linkend="ch0117s0009s0002li0022">22</link>).</para>
        <anchor id="ch0117s0005s0002a0004"/>
        <beginpage pagenum="1905"/>
        <figure id="ch0117s0005s0002f0001"><title><anchor id="ch0117s0005s0002a0005"/><phrase role="figureLabel"><anchor id="ch0117s0005s0002a0006"/><link linkend="ch0117s0005s0002a0003">FIGURE 4</link></phrase> IFA for WNV-infected Vero cells using a flavivirus group-specific mouse MAb (6B6C1) and, as the detector, anti-mouse IgG antibody conjugated to fluorescein dye (6-carboxyfluorescein).
</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0117f04.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <para id="ch0117s0005s0002p0002">Novel methods for virus identification, such as deep sequencing, ultradeep sequencing, and amplicon sequencing (sequencing the same DNA target amplicons many times to find rare mutations), may enhance the identification of new species or families of viruses from tissue, arthropods, or blood. Sequencing provides the advantage of identifying new subtypes of existing viruses or new species in vectors or vertebrate hosts prior to their emergence in the human population. Viruses that may rapidly evolve to infect humans as their amplifying or dead-end incidental host can be rapidly identified for prevention and control measures. For example, Swei et al. reconstructed a newly discovered virus in less than 24 h, which was significantly faster than conventional sequencing techniques (<link linkend="ch0117s0009s0002li0123">123</link>). These researchers identified the Lone Star virus, in the genus <emphasis>Bandavirus</emphasis>; this virus is carried by <emphasis>Amblyomma americanum</emphasis> ticks and is related to the Heartland virus, which was responsible for an illness reported among farmers in Missouri (<link linkend="ch0117s0009s0002li0033">33</link>).</para>
      </sect2>
      <sect2 id="ch0117s0005s0003">
        <title>SEROLOGICAL TESTS</title>
        <anchor id="ch0117s0005s0003a0001"/>
        <anchor id="ch0117s0005s0003a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0117s0006">
      <title>HIA</title>
      <anchor id="ch0117s0006a0001"/>
      <anchor id="ch0117s0006a0002"/>
      <para id="ch0117s0006p0001">The hemagglutination inhibition assay (HIA) is a classic test used for arbovirus diagnostics and was the basis for virus family classification prior to genome sequencing. The test was first described in 1958 by Clarke and Casals and adapted to a microtiter plate format in 1980 (<link linkend="ch0117s0009s0002li0124">124</link>). HIA is not antibody isotype specific; thus, it does not differentiate between IgM and IgG. The presence of antiarbovirus antibodies in host serum specimens inhibits the agglutination of goose erythrocytes, as observed by a button-like appearance of the erythrocytes in the 96-well microtiter plate. Defining a positive HIA titer is influenced by the titer of the positive control used in the test and the infection status (primary or secondary infection by an arbovirus within the same genus). The results are subjective and vary by the experience of the laboratory technical staff performing the test.</para>
      <para id="ch0117s0006p0002">The main advantage of the HIA is that it can be used for surveillance involving multiple hosts, since the test is not species specific. Thus, the HIA is used for vertebrate sentinel surveillance in laboratories that detect multiple cocirculating arboviruses. ELISAs have essentially replaced the HIA in human specimen testing due to the difficulty of standardizing HIA reagents and buffers and the availability of goose erythrocytes. Additionally, the interpretation of the results of HIA is subjective, and cross-reactivity between viruses within the same group or subgroup yields nonspecific results.</para>
    </sect1>
    <sect1 id="ch0117s0007">
      <title>ELISA</title>
      <anchor id="ch0117s0007a0001"/>
      <anchor id="ch0117s0007a0002"/>
      <sect2 id="ch0117s0007s0001">
        <title>IgM ELISA</title>
        <anchor id="ch0117s0007s0001a0001"/>
        <anchor id="ch0117s0007s0001a0002"/>
        <para id="ch0117s0007s0001p0001">The acquired immune response to an arbovirus infection initially results in the synthesis of IgM antibody isotype. IgM is detectable in the late acute and the convalescent phases of the infection and is an indication of an acute or recent arbovirus infection. The IgM antibody capture (MAC) ELISA format is preferred by most diagnostic laboratories and commercial diagnostic kits. There are two main reasons for their widespread use. First, the MAC ELISA captures IgM antibodies on a microtiter plate using an anti-human-IgM antibody, thus minimizing the interference of the high-avidity IgG antibodies with binding to the antigen. Second, the MAC ELISA removes nonspecific antibody binding, allowing the use of many different sources of antigen, including unpurified homogeneous protein products composed of a mixture of viral antigens. In the MAC ELISA format, the excess antigen in combination with broadly cross-reactive MAbs that are generally arbovirus group specific increases the sensitivity of the test. Another advantage of the MAC ELISA format is that antigens can be interchanged to compare patient antibody responses to different arboviruses within the same family, mainly due to the use of broadly cross-reactive MAbs conjugated to a detector molecule. The MAC ELISA is highly sensitive but has variable specificity, depending on the cross-reactivity of cocirculating arboviruses. For example, in regions where DENV, JEV, and/or ZIKV cocirculate, there is a high degree of cross-reactivity in IgM ELISA results that typically requires confirmation testing by neutralization assay.</para>
        <anchor id="ch0117s0007s0001a0003"/>
        <beginpage pagenum="1906"/>
        <para id="ch0117s0007s0001p0002">During the acute phase of the infection (the first 5 DPO), a relatively small percentage (~≤10%) of patients have detectable IgM antibodies; however, this varies and is dependent on when the specimen is obtained following initial symptoms, other underlying conditions of the patient, and the arbovirus (<link linkend="ch0117s0009s0002li0125">125</link>). IgM antibody titer peaks in the convalescent phase of the infection (6 to 14 DPO); thus, antibody testing during this period yields the most reliable results. However, IgM antibody kinetics can vary by arbovirus family, genus, and species, infection status, and specimen type. For example, patients with secondary DENV infections (i.e., those with &gt;1 DENV infection) had lower IgM titers than those with primary DENV infections (<link linkend="ch0117s0009s0002li0126">126</link>). In these unique cases where secondary infection resulted in lower IgM titers, the presence of IgG in an acute specimen could be used to inform timing of infection (<link linkend="ch0117s0009s0002li0127">127</link>). For encephalitic arboviruses, the detection of IgM antibodies in CSF differs from detection in sera. Anti-JEV IgM is detectable in sera approximately 9 to 13 days following the onset of symptoms; however, in the CSF, IgM is detectable as early as 1 day after onset of symptoms (<link linkend="ch0117s0009s0002li0128">128</link>). Burke et al. determined that when HAI is used as the only diagnostic test to confirm JE in clinical serum specimens, it missed 34% of JE cases compared to the MAC ELISA (<link linkend="ch0117s0009s0002li0129">129</link>). In addition, anti-JEV IgM antibodies can persist in the CSF for as long as a year, suggesting persistent JEV infection of the CNS (<link linkend="ch0117s0009s0002li0130">130</link>). In other atypical cases, the IgM response may persist for &gt;3 months, as observed with WNV, ZIKV, and JEV infections (60, 131–133). A prospective assessment of WNV IgM persistence demonstrated that WNV IgM could be detected more than 5 years after symptom onset (<link linkend="ch0117s0009s0002li0134">134</link>). IgM persistence observed with some arbovirus infections has prompted the development of IgG antibody avidity tests to assess the infection status (acute, recent, or past) (<link linkend="ch0117s0009s0002li0135">135</link>). Other assays, such as the detection of IgA as an alternate antibody isotype, could be considered if antibody persistence is suspected.</para>
        <para id="ch0117s0007s0001p0003">The sensitivity and specificity of the MAC ELISA are dependent on the source of the viral antigen, the detector antibody, the conjugated chromogen, serum condition (unacceptable serum samples include those that have undergone hemolysis, are lipemic, or are contaminated with bacteria or fungi), and the specimen dilution factor. The viral antigens source is by far the most important factor to consider for sensitivity and specificity of the test. Prior to<emphasis>in vitro</emphasis> system recombinant antigen production in bacterial or mammalian expression vectors, many of the viral antigens for arboviruses were produced by virus inoculation in SMB or virus-infected cell culture lysate. SMB-derived antigens provide the highest sensitivity in the MAC ELISA because they are composed of a high-titer mixture of all viral antigens, yet they provide the least specificity due to their impurity. Conversely, recombinant antigens, developed from immunogenic structural gene products, can be less sensitive yet provide better test specificity. Recombinant antigens that maintain the native conformation or glycosylation state of arbovirus structural proteins, which are essential for antibody binding, tend to provide the most sensitive and specific test results.</para>
        <para id="ch0117s0007s0001p0004">There are a variety of available commercially manufactured IgM ELISAs and rapid lateral-flow assays for some arboviruses, such as ZIKV, WNV, JEV, YFV, and DENV, with various sensitivities and specificities (<link linkend="ch0117s0009s0002li0136">136</link>–<link linkend="ch0117s0009s0002li0138">138</link>). For some of the less common arboviruses, many of the arbovirus reference and public health diagnostic laboratories may use laboratory developed IgM tests. Some of these commercial tests have very good sensitivity and specificity compared to gold standard or reference tests. Prior to implementing a commercial assay, each diagnostic laboratory should perform a comprehensive independent evaluation (<link linkend="ch0117s0009s0002li0139">139</link>).</para>
      </sect2>
      <sect2 id="ch0117s0007s0002">
        <title>IgG ELISA</title>
        <anchor id="ch0117s0007s0002a0001"/>
        <anchor id="ch0117s0007s0002a0002"/>
        <para id="ch0117s0007s0002p0001">The presence of anti-arbovirus IgG antibodies in a specimen is an indication of a long-term acquired immunity from a past arbovirus infection. IgG antibodies have been shown for certain arboviruses to be detected for up to 60 years after the initial infection (<link linkend="ch0117s0009s0002li0140">140</link>). There are two primary methods to measure IgG, direct and indirect ELISA. Direct IgG ELISA is less sensitive than indirect ELISA; it requires purified viral antigen and is rarely used. The indirect IgG ELISA is more sensitive and uses a capture antibody to immobilize the viral antigen on a solid surface. This capture step is especially important for unpurified antigens generated from virus infection of SMB, since this antigen is less immunogenic unless it has been captured and concentrated (<link linkend="ch0117s0009s0002li0141">141</link>). In the indirect assay, the specimen is added to the captured viral antigen and then detected with an enzyme-conjugated secondary anti-human-IgG antibody. The IgG ELISA results are reported as either qualitative or quantitative or as endpoint dilutions. However, due to cross-reactivity within families and between species of viruses, the IgG ELISA lacks specificity and may require additional confirmatory testing, such as a neutralization test for virus identification. The IgG ELISA binds all available anti-arbovirus IgG (neutralizing and nonneutralizing antibodies); hence, the test tends to be more sensitive and less specific than the plaque reduction neutralization test (PRNT), in which only neutralizing antibodies effectively bind to the virus and block viral entry into susceptible cells. Similar to the IgM assays, arbovirus-specific IgG detection in serum specimens can also be detected using IFA.</para>
        <para id="ch0117s0007s0002p0002">Some investigators have explored the use of structural antigens other than the envelope protein, such as the nonstructural gene products NS1 and membrane proteins, to increase the specificity of the IgG ELISA between flaviviruses. One study demonstrated that anti-NS1 IgG responses waned significantly within 1.5 to 2 years after ZIKV infection, demonstrating that different antigenic targets could show variable positivity rates and could be coupled to inform timing of infection (<link linkend="ch0117s0009s0002li0142">142</link>). Cardosa et al. demonstrated that the IgG response to premembrane protein has greater specificity for differentiating between DENV and JEV (<link linkend="ch0117s0009s0002li0143">143</link>). Other researchers have improved the specificity of the IgG ELISA by targeting the immunogenic epitope of the envelope protein using a recombinant polypeptide located in the N-terminal portion of the envelope protein, specifically EDIII (<link linkend="ch0117s0009s0002li0144">144</link>). Other assays, such as IgG avidity ELISAs, have proven useful in differentiating primary versus secondary flavivirus infection (<link linkend="ch0117s0009s0002li0145">145</link>, <link linkend="ch0117s0009s0002li0146">146</link>). The avidity assay uses a stringent 3 to 6 M urea wash buffer to remove nonspecific IgG binding. This stringent wash step has been useful in differentiating acute from past arbovirus infections under unique circumstances in which the IgM response persists (<link linkend="ch0117s0009s0002li0135">135</link>, <link linkend="ch0117s0009s0002li0147">147</link>). Following the Zika virus pandemic in the Americas, where dengue was hyperendemic in many of the countries where Zika was circulating, the cross-reactivity between these two viruses became a diagnostic challenge, especially when serological tests were used (<link linkend="ch0117s0009s0002li0148">148</link>, <link linkend="ch0117s0009s0002li0149">149</link>). Researchers found that detecting anti-NS1 IgG provided improved specificity compared to assays using the structural protein antigens, such as envelope, capsid, or membrane proteins. Several studies have shown that anti-NS1 IgG is specific for detecting prior Zika virus infection (98, 150–152).</para>
        <anchor id="ch0117s0007s0002a0003"/>
        <beginpage pagenum="1907"/>
        <para id="ch0117s0007s0002p0003">IgG subclasses have been studied as markers of disease severity (<link linkend="ch0117s0009s0002li0153">153</link>–<link linkend="ch0117s0009s0002li0155">155</link>). For JEV, subclass IgG1 is the most abundant antibody in the CSF following confirmed cases of clinical encephalitis. Thakare et al. were unable to detect IgG2 in sera or CSF of JE patients and postulated that the IgG1 subclass is more cytophilic than other IgG subclasses and may be more effective in viral clearance (<link linkend="ch0117s0009s0002li0153">153</link>). For DEN patients, IgG1 and IgG4 subclasses are risk markers for the development of dengue hemorrhagic fever and dengue shock syndrome (the more severe presentation of the disease). An article by Wang et al. identified IgG1 as a significant risk for thrombocytopenia (<link linkend="ch0117s0009s0002li0156">156</link>).</para>
      </sect2>
      <sect2 id="ch0117s0007s0003">
        <title>IgA ELISA</title>
        <anchor id="ch0117s0007s0003a0001"/>
        <anchor id="ch0117s0007s0003a0002"/>
        <para id="ch0117s0007s0003p0001">Immunoglobulin A (IgA) antibody detection has also been used to test for recent flaviviral infection, primarily for DENV and JEV. Most tests for IgA use saliva samples rather than serum samples, although both types of samples have been used. Saliva is an attractive alternative to blood, and it has been used successfully as a diagnostic tool for other viral diseases, such as hepatitis A and B, rubella, measles, mumps, and human immunodeficiency viruses (<link linkend="ch0117s0009s0002li0157">157</link>) and even severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (<link linkend="ch0117s0009s0002li0158">158</link>). Two IgA types (IgA1 and IgA2) are detected. IgA1 is found primarily in serum, and IgA2 is found primarily in the saliva, tears, and colostrum. Several studies have compared the sensitivity of detecting IgA versus IgM in both serum and saliva. These studies demonstrated that IgA in saliva had a 69% concordance, compared to a 74% concordance in serum for DENV (<link linkend="ch0117s0009s0002li0159">159</link>). IgA sensitivity during the first 29 days of illness was found to be 48% (<link linkend="ch0117s0009s0002li0160">160</link>). The percentage of patients found to have JEV IgA antibodies in their serum compared to saliva differed dramatically, with 25% of confirmed patients having detectable IgA in their serum and none in their saliva (<link linkend="ch0117s0009s0002li0161">161</link>). A subsequent study found that 37% of acute JEV patients had detectable IgA in their serum and 40% in their CSF, with IgA levels in the CSF of these patients being significantly lower than IgM levels (<link linkend="ch0117s0009s0002li0162">162</link>). Because IgA detection is, in general, less sensitive than IgM, IgA has not been incorporated into routine flaviviral diagnostics; nevertheless, multiple studies have shown that IgA detection in host serum specimens provides a specific response to flaviviruses. Due to the persistence of the IgM response in many flaviviruses, IgA detection could be an attractive target indicator of acute flavivirus infection. For other arboviruses (alphavirus and orthobunyaviruses), IgA responses have not been studied, and thus, no information on the utility of this antibody isotype for timing of acute and/or recent infections is available.</para>
      </sect2>
      <sect2 id="ch0117s0007s0004">
        <title>Competition/Inhibition ELISAs</title>
        <anchor id="ch0117s0007s0004a0001"/>
        <anchor id="ch0117s0007s0004a0002"/>
        <para id="ch0117s0007s0004p0001">There are several competition ELISAs used for arboviruses, also referred to as inhibitory and/or blocking ELISA formats. These ELISAs measure the magnitude of virus-specific antibodies generated by the host sera by detecting the interference directed toward an expected signal outcome. The ELISA is optimized with a known quantity of competing labeled antibody; hence, the higher the antibody titer in the specimen, the weaker the output signal. Therefore, the output signal inversely correlates with the concentration of antibody in the specimen. Unlike conventional ELISAs, which use chromogens to induce a colorimetric readout to convey a positive result, blocking or competition ELISA positivity relies on the absence of output signal. Although these ELISA formats have been successfully used for WNV for animal surveillance where species-specific antibodies were not available, these competition methods have not been commonly used to characterize WNV infection in humans (<link linkend="ch0117s0009s0002li0163">163</link>). Blocking ELISAs specific for DENV, ZIKV, and CHIKV as a human diagnostic tool have been developed and may have improved specificity compared to the conventional indirect or sandwich ELISAs (<link linkend="ch0117s0009s0002li0164">164</link>, <link linkend="ch0117s0009s0002li0165">165</link>). The blockade-of-binding test that detects flavivirus anti-NS1 antibodies has been used to differentiate ZIKV from DENV in countries where dengue is endemic during the ZIKV pandemic in 2016 in the Americas due to the high cross-reactivity between DENV and ZIKV (<link linkend="ch0117s0009s0002li0166">166</link>). This assay uses monoclonal antibodies directed against the S2 region of the NS1 nonstructural protein to specifically identify antibodies to ZIKV. The results from these studies were promising with regard to identifying a simple method to differentiate serologically positive specimens and avoid the need for confirmation of serological results with costly and technically challenging neutralization tests; however, the methodology of using a test where a negative reaction conveys a positive result presents multiple limitations, especially when the test has not been properly optimized. Therefore, these tests are not recommended for routine clinical diagnostics.</para>
      </sect2>
      <sect2 id="ch0117s0007s0005">
        <title>Indirect Immunofluorescence Assays</title>
        <anchor id="ch0117s0007s0005a0001"/>
        <anchor id="ch0117s0007s0005a0002"/>
        <para id="ch0117s0007s0005p0001">Indirect immunofluorescence assays have also been used to assess antibody reactivity against arboviruses. These tests consist of arbovirus-infected cells that are affixed or spotted onto a glass microscope slide. Dilutions of the patient serum or CSF specimen is then added to the prepared slide and incubated for designated time-period; then, the slide is washed several times to remove excess antibodies, and a fluorescently labeled anti-human IgM or IgG MAb is added. The result is a subjective determination of fluorescently stained cells observed by microscopic analysis. The report may also include semi-quantitative end-point titer information.</para>
        <para id="ch0117s0007s0005p0002">IgM and IgG indirect immunofluorescence assays for California serogroup orthobunyaviruses, Eastern Equine Encephalitis Virus, Western Equine Encephalitis Virus and St. Louis Encephalitis Virus (Arbovirus IFA IgM and Arbovirus IFA IgG; Focus Diagnostics) are available at commercial reference laboratories. These tests are FDA-cleared for serum specimens but are also available as laboratory-developed tests for CSF.</para>
      </sect2>
      <sect2 id="ch0117s0007s0006">
        <title>Microsphere Immunoassays</title>
        <anchor id="ch0117s0007s0006a0001"/>
        <anchor id="ch0117s0007s0006a0002"/>
        <para id="ch0117s0007s0006p0001">Given that arboviruses frequently co-circulate regionally, and infected patients often present with similar signs and symptoms, the multiplexing of arbovirus serologic testing may be of clinical use. One serologic method that has been utilized for the multiplexed detection of IgM and IgG antibodies against arboviruses is microsphere immunoassay (MIA) technology (Luminex/DiaSorin). In these assays, fluorescently-labeled, spectrally-addressed microspheres are coupled to group-reactive MAbs, which are then used to capture viral antigens prepared via infection of the suckling mouse brain or via recombinant protein expression in cell culture. These viral antibody/antigen-complexed microspheres are then incubated with patient serum or CSF. Finally, Ffluorescently-labeled anti-human IgM or IgG antibodies are added, and the microspheres with bound patient antibodies are detected using a multiplex immunoassay system (BioRad Bioplex) that reads fluorescence from both the microspheres and secondary antibodies.</para>
        <anchor id="ch0117s0007s0006a0003"/>
        <beginpage pagenum="1908"/>
        <para id="ch0117s0007s0006p0002">This approach was utilized to develop duplex West Nile Virus/St. Louis Encephalitis Virus IgM and IgG MIAs (<link linkend="ch0117s0009s0002li0167">167</link>, <link linkend="ch0117s0009s0002li0168">168</link>), as well as mulitplex arbovirus IgM and IgG MIAs for 13 arboviruses (<link linkend="ch0117s0009s0002li0169">169</link>). The multiplex arbovirus MIAs demonstrated particular utility for diagnosis of Eastern Equine Encephalitis in a set of cases in Connecticut, where indirect immunofluorescence was falsely negative (<link linkend="ch0117s0009s0002li0170">170</link>). Arbovirus MIA testing is available at arbovirus laboratory of the Centers for Disease Control and Prevention in Fort Collins, Colorado.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0117s0008">
      <title>Viral Neutralization Tests</title>
      <anchor id="ch0117s0008a0001"/>
      <anchor id="ch0117s0008a0002"/>
      <para id="ch0117s0008p0001">The PRNT is the most specific serological test for the determination of type-specific antibodies and is most often used to confirm immunodiagnostic test results to determine the infecting arbovirus in convalescent-phase sera (<link linkend="ch0117s0009s0002li0171">171</link>). This biological assay utilizes the specific interaction of virus and antibody <emphasis>in vitro</emphasis>, resulting in the inactivation of the virus such that it is no longer able to infect and replicate in cell culture. PRNT results are presented as the endpoint titer of neutralizing antibodies from serum to a specific virus and may suggest the level of immune protection against the infecting virus. Positive titer results from the PRNT are associated with immune protection in vaccine studies and confirm the infecting virus for IgM- or IgG-positive specimens.</para>
      <para id="ch0117s0008p0002">Antibody neutralization has been studied extensively in animal models, natural infections in humans, and<emphasis>in vitro</emphasis> cell culture experiments. Neutralizing antibodies are primarily directed against the structural proteins of the virus. The neutralization epitopes for flaviviruses are located throughout the E glycoprotein, including domain I, domain II, and the surface of domain III (<link linkend="ch0117s0009s0002li0172">172</link>–<link linkend="ch0117s0009s0002li0174">174</link>). For alphaviruses, the neutralizing epitopes have been mapped primarily to the E2 envelope protein, which is also important for receptor binding and cell entry. E2 epitope clustering in the glycoprotein has been identified for VEEV and Sindbis and Ross River viruses (<link linkend="ch0117s0009s0002li0175">175</link>, <link linkend="ch0117s0009s0002li0176">176</link>). Neutralizing epitopes are found within the G1 glycoprotein for bunyaviruses (<link linkend="ch0117s0009s0002li0177">177</link>).</para>
      <para id="ch0117s0008p0003">Viral neutralization requires that multiple antibodies occupy the surface of the virion to inhibit the viral infection. This is referred to as the multihit theory (<link linkend="ch0117s0009s0002li0178">178</link>, <link linkend="ch0117s0009s0002li0179">179</link>). A homologous antibody response would be more effective in virus neutralization than a heterologous response. A combination of neutralizing, nonneutralizing, and subneutralizing antibodies has a synergistic effect. In other instances, heterologous antibodies are hypothesized to potentiate or enhance viral entry through Fc receptors, as observed with DENV and WNV (<link linkend="ch0117s0009s0002li0180">180</link>–<link linkend="ch0117s0009s0002li0182">182</link>).</para>
      <para id="ch0117s0008p0004">Flaviviruses have both group-specific and type-specific antibody neutralization determinants. The type-specific determinants are cross-reactive in heterologous reactions, causing the cross-reactivity observed in serological IgM and IgG tests. The neutralizing antibody titer required for protective immunity is still not well understood. Vaccine studies have provided information on protective antibody titers for flaviviruses such as YFV, JEV, and DENV; however, many of these studies were of primary infections with attenuated vaccine strains.</para>
      <para id="ch0117s0008p0005">The PRNT results are suggestive of the infecting virus; therefore, PRNT is used to differentiate the infecting virus when cross-reactivity is observed in IgM and IgG tests. Because of the length of time required to perform a PRNT, 5 to 10 days, depending on the virus, it is not typically used as a clinical diagnostic test. Additionally, this test is not routinely performed in most diagnostic laboratories because it is expensive and requires a tissue culture facility and highly skilled technical staff. To obtain reliable and reproducible PRNT results, laboratories must standardize viral strains and cell lines. Unfortunately, there is no consensus as to the percentage of antibody-induced plaque reduction that constitutes a positive result in these tests. Different laboratories set endpoint values of 50%, 70%, or 90% reduction of the total input plaque-forming virus. Each of these endpoint values provides a different level of sensitivity and specificity; thus, although a 90% reduction in plaques provides the highest specificity, it is often less sensitive. In vaccine studies, a 50% reduction in plaques provides the sensitivity needed because of the relatively low neutralization titer produced following vaccination with attenuated strains of viruses in naive subjects. The challenge of PRNT is the standardization among all end users. Three variables account for most of the inconsistent results observed between laboratories: interpretation of the results (using 50, 70, or 90% plaque reduction as the endpoint), the cell lines used in the test, the laboratory viral strains and growth as well as the presence or absence of complement. In an attempt to standardize the PRNT worldwide for DENV, subject matter experts from around the world published guidelines for PRNT standardization (<link linkend="ch0117s0009s0002li0183">183</link>). In these guidelines, it was advised that viral growth be standardized such that virus is harvested prior to the plateau of growth 5 to 7 days postinfection.</para>
      <para id="ch0117s0008p0006">IgG depletion has been used to improve specificity of the PRNT. IgG depletion of the specimen has been performed using protein G Sepharose beads or columns. Once the IgG is depleted from the specimen, it is tested by neutralization assay such that the neutralization measured is specifically from the IgM antibodies in the specimen. This test was used for the analysis of suspected WNV cases in Puerto Rico where DENV is hyperendemic; thus, the DENV background in humans was very high and differentiating a DENV infection from WNV infection was not possible with detection of IgM alone (<link linkend="ch0117s0009s0002li0184">184</link>). During the ZIKV outbreak in the Americas in 2016, the same issues with high DENV background were observed. Calvert et al. successfully used a similar technique to measure the specificity of the IgM response in suspected ZIKV patients (<link linkend="ch0117s0009s0002li0185">185</link>), indicating its utility to differentiate secondary flavivirus infections. Nevertheless, this technique is still considered a research tool and not currently used for clinical diagnostics.</para>
    </sect1>
    <sect1 id="ch0117s0009">
      <title>Other Neutralization Tests</title>
      <anchor id="ch0117s0009a0001"/>
      <anchor id="ch0117s0009a0002"/>
      <para id="ch0117s0009p0001">The microneutralization test (MNT), the fluorescent focus assay (FFA) (also referred to as the fluorescence neutralization test [FRNT]), and the virus reduction neutralization test (VRNT) are other formats that are commonly used to detect neutralizing antibodies to specific viruses. The MNT relies on an ELISA-based assay format using a 96-well microtiter plates (<link linkend="ch0117s0009s0002li0186">186</link>–<link linkend="ch0117s0009s0002li0188">188</link>). This assay is based on the same neutralization principle as the PRNT; however, counting of plaques is replaced with a colorimetric measurement of virus infection to determine the endpoint dilution of the patient sample. This automates the process, and calorimetric output is typically measurable days before plaques could conventionally be enumerated. Briefly, susceptible cells are plated onto 96-well microtiter formatted plates and inoculated with a previously incubated mixture containing both virus and serum sample. The cells are fixed, and virus replication is measured by an ELISA with either a group- or type-specific monoclonal antibody or by detecting viral growth foci directly from reporter molecules expressed by the engineered virus used in the assay. In other formats, neutral red dye has been used as the measured chromogen. The neutralization is measured by either optical density (for a colorimetric reading) or fluorescence or enumerating reporter virus foci using automated approaches. The percent inhibition is determined based on the virus positive control, and a graph of the optical density by serum dilution is produced. The endpoint dilution either is calculated by using a logistical regression curve for an absolute value or is the serum dilution which is within 2 standard deviations below the cutoff value determined with the virus control (<link linkend="ch0117s0009s0002li0186">186</link>, <link linkend="ch0117s0009s0002li0189">189</link>).</para>
      <anchor id="ch0117s0009a0003"/>
      <beginpage pagenum="1909"/>
      <para id="ch0117s0009p0002">The major advantages of the MNT are that it requires less serum and fewer reagents, can be automated for high-throughput testing, and provides a more rapid result. In addition, the 96-well microtiter plate format allows more serum dilutions, increasing the probability of reaching an endpoint dilution. Limitations of the assay include a low correlation with PRNT, especially in secondary flavivirus infections (<link linkend="ch0117s0009s0002li0189">189</link>).</para>
      <para id="ch0117s0009p0003">The difference between PRNT and the FFA (or FRNT) is that the former requires formation of plaques, while the FFA test relies on early stages of the infection in culture prior to plaque formation (<link linkend="ch0117s0009s0002li0190">190</link>). Both assays require the use of susceptible-cell infection; however, the FFA endpoint is the visualization of virus-infected cells detected by a fluorophore (or reporter molecule). Because detection of infected cells occurs within 1 to 2 days, the assay has been favored over classic plaque formation assays. In addition, this assay detects viruses that perhaps do not easily form plaques; thus, it could be used to assess broader neutralization potential on cell types that would not typically be used for plaque formation with a specific virus. This format has been readily adopted for vaccine efficacy studies due to its higher throughput capacity, the ability to identify viruses that do not form plaques, and the use of automated imaging systems to count fluorescent foci. This automation step removes the human error factor and subjectivity often observed with the PRNT technique when reading individual plaques. The VRNT is a modification of the FFA/FRNT that incorporates higher-throughput automation to count infected cells. The VRNT was developed for DENV vaccine trials (<link linkend="ch0117s0009s0002li0191">191</link>). Using wild-type viruses and immunostaining, the VRNT is similar to FFA/FRNT; however, to improve throughput and reduce subjectivity of the assay, the VRNT uses imaging cytometry to count virus-infected cells at 1 day postinfection, eliminating the issue of overlapping foci and improving precision and accuracy of the test.</para>
      <sect2 id="ch0117s0009s0001">
        <title>EVALUATION, INTERPRETATION, AND REPORTING OF RESULTS</title>
        <anchor id="ch0117s0009s0001a0001"/>
        <anchor id="ch0117s0009s0001a0002"/>
        <para id="ch0117s0009s0001p0001">The testing algorithm for diagnosing acute arboviral infection is a matrix divided according to acute-phase and convalescent-phase specimen collection (<link linkend="ch0117s0001s0005a0010">Fig. 3</link>). The acute-phase specimen (i.e., serum or CSF specimen ≤5 DPO) is tested for the presence of virus by NAAT, virus isolation, or viral antigen tests or for IgM in CSF for encephalitic viruses. The convalescent-phase specimen (i.e., serum or CSF specimen &gt;5 to &lt;14 DPO) is tested for the presence of IgM and IgG antibodies. An acute arbovirus infection is defined as the detection of virus or viral RNA by isolation or NAAT, respectively, or seroconversion by IgM and/or IgG testing. A single specimen with an IgM-positive test result is suggestive of a recent infection; however, there are several exceptions, especially WNV and ZIKV infections, where there is IgM persistence beyond 120 days (<link linkend="ch0117s0009s0002li0060">60</link>, <link linkend="ch0117s0009s0002li0133">133</link>). Cases of viral RNA persistence have also been reported, notably for WNV, ZIKV, and Colorado tick fever virus. The detection of only IgG in a specimen is an indication of a previous infection unless there are paired specimens (acute and convalescent phase) indicating a seroconversion. IgM seroconversion in paired specimens is defined as a negative test result in the acute-phase specimen followed by a positive test result in the convalescent-phase specimen. IgG seroconversion is defined the same way or as a 4-fold rise in IgG titer from the acute-phase specimen to the convalescent-phase specimen, with a minimum of 5 days between collected specimens. Because of the high degree of cross-reactivity observed within arbovirus genera (especially flaviviruses), serological results are generally confirmed with neutralization tests when definitive diagnosis is required. However, there are certain circumstances where PRNT cannot identify the infecting virus due to multiple exposures to antigenically similar viruses. Here, we provide a general guide to the arbovirus kinetics for nucleic acid detection and antibody detection for most arboviruses; nevertheless, there are always exceptions to consider when analyzing specific arboviruses that may not conform to the typical analyte detection periods (<link linkend="ch0117s0001s0005a0006">Fig. 2</link>).</para>
        <para id="ch0117s0009s0001p0002">The testing algorithm for other specialized epidemiological studies, including sero-incidence and/or serosurveys to measure the incidence or prevalence, respectively, in a population is different from that for diagnostics that define acutely ill patients; thus, diagnostic testing must be modified. Serosurvey studies assess the prevalence and sero-incidence of arboviruses by measuring the rate of infection within the population. Because these epidemiological studies rely on measuring acute, recent, and past infection, the testing algorithm and the interpretation of the test results differ and require other relevant study subject information, such as travel history, vaccination history, age, and other demographics, to accurately determine the prevalence or incidence of specific arbovirus infections within a particular population. Thus, decisions regarding the best test to use will be determined by study aim.</para>
        <para id="ch0117s0009s0001p0003">A variety of commercial tests have been developed for the detection of arboviruses. These tests include molecular, antibody, and antigen tests and IFAs. The formats vary from standard microtiter plate tests to rapid diagnostic tests with variable sensitivity and specificity, as evaluated by the manufacturer or by independent investigators. Advantages of commercial tests include standardization of the ancillary reagents, which allows reproducible results, and manufacturing of the tests using good manufacturing practice. Commercial tests may provide the end user with higher quality assurance, which is often difficult to obtain with in-house laboratory-developed tests (LDTs). However, commercial assays can vary in quality (from lot to lot) and in reliability (test availability). Companies may discontinue manufacturing these tests when the market is not profitable, leaving the end user, and reference laboratories in particular, with no other option than to maintain LDTs in their portfolio of tests. Additionally, commercial tests may be cost prohibitive in comparison to LDTs, resulting in a preference for using LDTs despite the fact that LDTs may not be as sensitive as their commercial counterparts. Other aspects of the tests unrelated to their performance that may determine their use in laboratories are the technical time needed to perform the test, storage requirements, reagent stability, and ease of use.</para>
        <anchor id="ch0117s0009s0001a0003"/>
        <beginpage pagenum="1910"/>
        <para id="ch0117s0009s0001p0004">The decision to use commercial assays is country dependent, as regulatory agencies in each country maintain different approval standards and the availability of tests varies geographically. U.S. commercial laboratories prefer to use U.S. Food and Drug Agency (FDA)-approved tests for clinical diagnostics; however, this is not mandatory as long as the tests meet Clinical Laboratory Improvement Amendments and College of American Pathologists standards for validation. To reduce duplicative efforts, some countries rely on the FDA regulatory approval process for the use of commercially available tests for clinical diagnosis. Other countries have developed their own internal assessment requirements. There are limited available commercial tests for most arboviruses, with the exception of DENV, JEV, CHIKV, ZIKV, and WNV, and even fewer FDA-approved tests. Although many of these tests claim good performance with high sensitivity and specificity, independent evaluations to corroborate the company’s results are important. Recent studies involving DENV diagnostics for both IgM tests and NS1 tests determined that the performance of some companies’ tests was below the acceptable range for use. These studies also determined that tests that depend on subjective reading of results, such as rapid diagnostic tests, often have large variation due to reader-to-reader variation (<link linkend="ch0117s0009s0002li0136">136</link>). Thus, diagnostic laboratories must develop a plan to evaluate commercial tests prior to their implementation as routine diagnostic tools.</para>
        <para id="ch0117s0009s0001p0005">The conclusions are those of the authors and do not represent the opinions of the Centers for Disease Control and Prevention. Mention of trade names is for specific information only and does not imply endorsement by the Centers for Disease Control and Prevention.</para>
      </sect2>
      <sect2 id="ch0117s0009s0002">
        <title>REFERENCES</title>
        <anchor id="ch0117s0009s0002a0001"/>
        <anchor id="ch0117s0009s0002a0002"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0117s0009s0002li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Chen R, Mukhopadhyay S, Merits A, Bolling B, Nasar F, Coffey LL, Powers A, Weaver SC, ICTV Report Consortium.</emphasis> 2018. ICTV Virus Taxonomy Profile: togaviridae. <citetitle><emphasis>J Gen Virol</emphasis></citetitle> <emphasis role="strong">99:</emphasis>761–762.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Garrison AR, Alkhovsky</emphasis> Альховский Сергей Владимирович <emphasis role="strong">SV, Avši</emphasis>č<emphasis role="strong">-Županc T, Bente DA, Bergeron É, Burt F, Di Paola N, Ergünay K, Hewson R, Kuhn JH, Mirazimi A, Papa A, Sall AA, Spengler JR, Palacios G, ICTV Report Consortium.</emphasis> 2020. ICTV virus taxonomy profile: <citetitle><emphasis>Nairoviridae. J Gen Virol</emphasis></citetitle> <emphasis role="strong">101:</emphasis>798–799.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Hughes HR, Adkins S, Alkhovskiy S, Beer M, Blair C, Calisher CH, Drebot M, Lambert AJ, de Souza WM, Marklewitz M, Nunes MRT, Shí X, ICTV Report Consortium.</emphasis> 2020. ICTV virus taxonomy profile: <citetitle><emphasis>Peribunyaviridae. J Gen Virol</emphasis></citetitle> <emphasis role="strong">101:</emphasis>1–2.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T, Muerhoff S, Pletnev A, Rico-Hesse R, Smith DB, Stapleton JT, ICTV Report Consortium.</emphasis> 2017. ICTV virus taxonomy profile: <citetitle><emphasis>Flaviviridae. J Gen Virol</emphasis></citetitle> <emphasis role="strong">98:</emphasis>2–3.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Albornoz A, Hoffmann AB, Lozach PY, Tischler ND.</emphasis> 2016. Early bunyavirus-host cell interactions. <citetitle><emphasis>Viruses</emphasis></citetitle> <emphasis role="strong">8:</emphasis>143.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E.</emphasis> 2002. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. <citetitle><emphasis>Virology</emphasis></citetitle> <emphasis role="strong">292:</emphasis>162–168.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Edgil D, Harris E.</emphasis> 2006. End-to-end communication in the modulation of translation by mammalian RNA viruses. <citetitle><emphasis>Virus Res</emphasis></citetitle> <emphasis role="strong">119:</emphasis>43–51.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Mazzon M, Jones M, Davidson A, Chain B, Jacobs M.</emphasis> 2009. Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">200:</emphasis>1261–1270.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Kalveram B, Lihoradova O, Indran SV, Lokugamage N, Head JA, Ikegami T.</emphasis> 2013. Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKR. <citetitle><emphasis>Virology</emphasis></citetitle> <emphasis role="strong">435:</emphasis>415–424.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Halstead SB.</emphasis> 2003. Neutralization and antibody-dependent enhancement of dengue viruses. <citetitle><emphasis>Adv Virus Res</emphasis></citetitle> <emphasis role="strong">60:</emphasis>421–467.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Tomashek KM, Rivera A, Muñoz-Jordan JL, Hunsperger E, Santiago L, Padro O, Garcia E, Sun W.</emphasis> 2009. Description of a large island-wide outbreak of dengue in Puerto Rico, 2007. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">81:</emphasis>467–474.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Busch MP, Caglioti S, Robertson EF, McAuley JD, Tobler LH, Kamel H, Linnen JM, Shyamala V, Tomasulo P, Kleinman SH.</emphasis> 2005. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">353:</emphasis>460–467.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Mohammed H, Linnen JM, Muñoz-Jordán JL, Tomashek K, Foster G, Broulik AS, Petersen L, Stramer SL.</emphasis> 2008. Dengue virus in blood donations, Puerto Rico, 2005. <citetitle><emphasis>Transfusion</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1348–1354.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Arragain L, Dupont-Rouzeyrol M, O’Connor O, Sigur N, Grangeon JP, Huguon E, Dechanet C, Cazorla C, Gourinat AC, Descloux E.</emphasis> 2017. Vertical transmission of dengue virus in the peripartum period and viral kinetics in newborns and breast milk: new data. <citetitle><emphasis>J Pediatric Infect Dis Soc</emphasis></citetitle> <emphasis role="strong">6:</emphasis>324–331.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Gérardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, Lenglet Y, Touret Y, Bouveret A, Grivard P, Le Roux K, Blanc S, Schuffenecker I, Couderc T, Arenzana-Seisdedos F, Lecuit M, Robillard PY.</emphasis> 2008. Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Réunion. <citetitle><emphasis>PLoS Med</emphasis></citetitle> <emphasis role="strong">5:</emphasis>e60.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Dupont-Rouzeyrol M, Biron A, O’Connor O, Huguon E, Descloux E.</emphasis> 2016. Infectious Zika viral particles in breastmilk. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">387:</emphasis>1051.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Hinckley AF, O’Leary DR, Hayes EB.</emphasis> 2007. Transmission of West Nile virus through human breast milk seems to be rare. <citetitle><emphasis>Pediatrics</emphasis></citetitle> <emphasis role="strong">119:</emphasis>e666–e671.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Armstrong P, Hennessey M, Adams M, Cherry C, Chiu S, Harrist A, Kwit N, Lewis L, McGuire DO, Oduyebo T, Russell K, Talley P, Tanner M, Williams C, Zika Virus Response Epidemiology and Laboratory Team.</emphasis> 2016. Travel-associated Zika virus disease cases among U.S. residents—United States, January 2015-February 2016. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">65:</emphasis>286–289.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Hills SL, Russell K, Hennessey M, Williams C, Oster AM, Fischer M, Mead P.</emphasis> 2016. Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission - continental United States, 2016. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">65:</emphasis>215–216.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Barbosa CM, Di Paola N, Cunha MP, Rodrigues-Jesus MJ, Araujo DB, Silveira VB, Leal FB, Mesquita FS, Botosso VF, Zanotto PMA, Durigon EL, Silva MV, Oliveira DBL.</emphasis> 2018. Yellow fever virus RNA in urine and semen of convalescent patient, Brazil. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>176-178.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Lalle E, Colavita F, Iannetta M, Gebremeskel Teklè S, Carletti F, Scorzolini L, Bordi L, Vincenti D, Castilletti C, Ippolito G, Capobianchi MR, Nicastri E.</emphasis> 2018. Prolonged detection of dengue virus RNA in the semen of a man returning from Thailand to Italy, January 2018. <citetitle><emphasis>Euro Surveill</emphasis></citetitle> <emphasis role="strong">23:</emphasis>18-00197.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Coffey LL, Forrester N, Tsetsarkin K, Vasilakis N, Weaver SC.</emphasis> 2013. Factors shaping the adaptive landscape for arboviruses: implications for the emergence of disease. <citetitle><emphasis>Future Microbiol</emphasis></citetitle> <emphasis role="strong">8:</emphasis>155–176.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0023" role="bibliographyEntry">
            <anchor id="ch0117s0009s0002a0003"/>
            <para>23.<emphasis role="strong">Steele KE, Linn MJ, Schoepp RJ, Komar N, Geisbert TW, Manduca RM, Calle PP, Raphael BL, Clippinger TL, Larsen T, Smith J, Lanciotti RS, Panella NA, McNamara TS.</emphasis> 2000. Pathology of fatal West Nile virus infections in native and exotic birds during the 1999 outbreak in New York City, New York. <citetitle><emphasis>Vet Pathol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>208–224.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, Vaney MC, Lavenir R, Pardigon N, Reynes JM, Pettinelli F, Biscornet L, Diancourt L, Michel S, Duquerroy S, Guigon G, Frenkiel MP, Bréhin AC, Cubito N, Desprès P, Kunst F, Rey FA, Zeller H, Brisse S.</emphasis> 2006. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. <citetitle><emphasis>PLoS Med</emphasis></citetitle> <emphasis role="strong">3:</emphasis>e263.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S.</emphasis> 2007. A single mutation in chikungunya virus affects vector specificity and epidemic potential. <citetitle><emphasis>PLoS Pathog</emphasis></citetitle> <emphasis role="strong">3:</emphasis>e201.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Stapleford KA, Moratorio G, Henningsson R, Chen R, Matheus S, Enfissi A, Weissglas-Volkov D, Isakov O, Blanc H, Mounce BC, Dupont-Rouzeyrol M, Shomron N, Weaver S, Fontes M, Rousset D, Vignuzzi M.</emphasis> 2016. Whole-genome sequencing analysis from the chikungunya virus Caribbean outbreak reveals novel evolutionary genomic elements. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e0004402.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Zanluca C, Melo VC, Mosimann AL, Santos GI, Santos CN, Luz K.</emphasis> 2015. First report of autochthonous transmission of Zika virus in Brazil. <citetitle><emphasis>Mem Inst Oswaldo Cruz</emphasis></citetitle> <emphasis role="strong">110:</emphasis>569–572.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Hayes EB.</emphasis> 2009. Zika virus outside Africa. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>1347–1350.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pretrick M, Marfel M, Holzbauer S, Dubray C, Guillaumot L, Griggs A, Bel M, Lambert AJ, Laven J, Kosoy O, Panella A, Biggerstaff BJ, Fischer M, Hayes EB.</emphasis> 2009. Zika virus outbreak on Yap Island, Federated States of Micronesia. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">360:</emphasis>2536–2543.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Schuler-Faccini L, Ribeiro EM, Feitosa IM, Horovitz DD, Cavalcanti DP, Pessoa A, Doriqui MJ, Neri JI, Neto JM, Wanderley HY, Cernach M, El-Husny AS, Pone MV, Serao CL, Sanseverino MT, Brazilian Medical Genetics Society–Zika Embryopathy Task Force.</emphasis> 2016. Possible association between Zika virus infection and microcephaly - Brazil, 2015. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">65:</emphasis>59–62.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">CDC.</emphasis> 2017. Yellow fever in Africa and the Americas, 2016. <citetitle><emphasis>Wkly Epidemiol Rec</emphasis></citetitle> <emphasis role="strong">92:</emphasis>442–452.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Kosoy OI, Lambert AJ, Hawkinson DJ, Pastula DM, Goldsmith CS, Hunt DC, Staples JE.</emphasis> 2015. Novel thogotovirus associated with febrile illness and death, United States, 2014. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>760–764.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Pastula DM, Turabelidze G, Yates KF, Jones TF, Lambert AJ, Panella AJ, Kosoy OI, Velez JO, Fisher M, Staples E, Centers for Disease Control and Prevention.</emphasis> 2014. Notes from the field: Heartland virus disease - United States, 2012-2013. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">63:</emphasis>270–271.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, Zhang L, Zhang QF, Popov VL, Li C, Qu J, Li Q, Zhang YP, Hai R, Wu W, Wang Q, Zhan FX, Wang XJ, Kan B, Wang SW, Wan KL, Jing HQ, Lu JX, Yin WW, Zhou H, Guan XH, Liu JF, Bi ZQ, Liu GH, Ren J, Wang H, Zhao Z, Song JD, He JR, Wan T, Zhang JS, Fu XP, Sun LN, Dong XP, Feng ZJ, Yang WZ, Hong T, Zhang Y, Walker DH, Wang Y, Li DX.</emphasis> 2011. Fever with thrombocytopenia associated with a novel bunyavirus in China. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">364:</emphasis>1523–1532.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Godsey MS Jr, Savage HM, Burkhalter KL, Bosco-Lauth AM, Delorey MJ.</emphasis> 2016. Transmission of Heartland virus Bunyaviridae: Phlebovirus) by experimentally infected Amblyomma americanum Acari: Ixodidae). <citetitle><emphasis>J Med Entomol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>1226–1233.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Savage HM, Godsey MS, Lambert A, Panella NA, Burkhalter KL, Harmon JR, Lash RR, Ashley DC, Nicholson WL.</emphasis> 2013. First detection of heartland virus Bunyaviridae: Phlebovirus) from field collected arthropods. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">89:</emphasis>445–452.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Savage HM, Burkhalter KL, Godsey MS Jr, Panella NA, Ashley DC, Nicholson WL, Lambert AJ.</emphasis> 2017. Bourbon virus in field-collected ticks, Missouri, USA. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">23:</emphasis>2017–2022.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Savage HM, Godsey MS Jr, Panella NA, Burkhalter KL, Manford J, Trevino-Garrison IC, Straily A, Wilson S, Bowen J, Raghavan RK.</emphasis> 2018. Surveillance for tick-borne viruses near the location of a fatal human case of Bourbon virus family Orthomyxoviridae: genus Thogotovirus) in eastern Kansas, 2015. <citetitle><emphasis>J Med Entomol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>701–705.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Hu YY, Zhuang L, Liu K, Sun Y, Dai K, Zhang XA, Zhang PH, Feng ZC, Li H, Liu W.</emphasis> 2020. Role of three tick species in the maintenance and transmission of severe fever with thrombocytopenia syndrome virus. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">14:</emphasis>e0008368.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH.</emphasis> 2011. Economic impact of dengue illness in the Americas. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">84:</emphasis>200–207.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A, Arvin-Berod C, Paganin F.</emphasis> 2008. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">47:</emphasis>469–475.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Sejvar JJ.</emphasis> 2014. Clinical manifestations and outcomes of West Nile virus infection. <citetitle><emphasis>Viruses</emphasis></citetitle> <emphasis role="strong">6:</emphasis>606–623.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Hazin AN, Poretti A, Di Cavalcanti Souza Cruz D, Tenorio M, van der Linden A, Pena LJ, Brito C, Gil LH, de Barros Miranda-Filho D, Marques ET, Turchi Martelli CM, Alves JG, Huisman TA, Microcephaly Epidemic Research Group.</emphasis> 2016. Computed tomographic findings in microcephaly associated with Zika virus. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">374:</emphasis>2193–2195.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL.</emphasis> 2016. Zika and the risk of microcephaly. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">375:</emphasis>1–4.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Miller E, Becker Z, Shalev D, Lee CT, Cioroiu C, Thakur K.</emphasis> 2017. Probable Zika virus-associated Guillain-Barré syndrome: challenges with clinico-laboratory diagnosis. <citetitle><emphasis>J Neurol Sci</emphasis></citetitle> <emphasis role="strong">375:</emphasis>367–370.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Sejvar JJ, Bode AV, Marfin AA, Campbell GL, Ewing D, Mazowiecki M, Pavot PV, Schmitt J, Pape J, Biggerstaff BJ, Petersen LR.</emphasis> 2005. West Nile virus-associated flaccid paralysis. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">11:</emphasis>1021–1027.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Sejvar JJ, Haddad MB, Tierney BC, Campbell GL, Marfin AA, Van Gerpen JA, Fleischauer A, Leis AA, Stokic DS, Petersen LR.</emphasis> 2003. Neurologic manifestations and outcome of West Nile virus infection. <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">290:</emphasis>511–515.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Beasley DW, Barrett AD, Tesh RB.</emphasis> 2013. Resurgence of West Nile neurologic disease in the United States in 2012: what happened? What needs to be done? <citetitle><emphasis>Antiviral Res</emphasis></citetitle> <emphasis role="strong">99:</emphasis>1–5.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Murray K, Baraniuk S, Resnick M, Arafat R, Kilborn C, Cain K, Shallenberger R, York TL, Martinez D, Hellums JS, Hellums D, Malkoff M, Elgawley N, McNeely W, Khuwaja SA, Tesh RB.</emphasis> 2006. Risk factors for encephalitis and death from West Nile virus infection. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">134:</emphasis>1325–1332.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Pang J, Hsu JP, Yeo TW, Leo YS, Lye DC.</emphasis> 2017. Diabetes, cardiac disorders and asthma as risk factors for severe organ involvement among adult dengue patients: a matched case-control study. <citetitle><emphasis>Sci Rep</emphasis></citetitle> <emphasis role="strong">7:</emphasis>39872.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Alvarado MG, Schwartz DA.</emphasis> 2017. Zika virus infection in pregnancy, microcephaly, and maternal and fetal health: what we think, what we know, and what we think we know. <citetitle><emphasis>Arch Pathol Lab Med</emphasis></citetitle> <emphasis role="strong">141:</emphasis>26–32.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Freitas DA, Souza-Santos R, Carvalho LMA, Barros WB, Neves LM, Brasil P, Wakimoto MD.</emphasis> 2020. Congenital Zika syndrome: a systematic review. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">15:</emphasis>e0242367.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Nascimento LB, Siqueira CM, Coelho GE, Siqueira JB Jr.</emphasis> 2017. Symptomatic dengue infection during pregnancy and livebirth outcomes in Brazil, 2007-13: a retrospective observational cohort study. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>949–956.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Pridjian G, Sirois PA, McRae S, Hinckley AF, Rasmussen SA, Kissinger P, Buekens P, Hayes EB, O’Leary D, Kuhn S, Swan KF, Xiong X, Wesson DM.</emphasis> 2016. Prospective study of pregnancy and newborn outcomes in mothers with West Nile illness during pregnancy. <citetitle><emphasis>Birth Defects Res A Clin Mol Teratol</emphasis></citetitle> <emphasis role="strong">106:</emphasis>716–723.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Kalayanarooj S.</emphasis> 2011. Clinical manifestations and management of dengue/DHF/DSS. <citetitle><emphasis>Trop Med Health</emphasis></citetitle> <emphasis role="strong">39</emphasis>Suppl)<emphasis role="strong">:</emphasis>83–87.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Yong LS, Koh KC.</emphasis> 2013. A case of mixed infections in a patient presenting with acute febrile illness in the tropics. <citetitle><emphasis>Case Rep Infect Dis</emphasis></citetitle> <emphasis role="strong">2013:</emphasis>562175.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Sharp TM, Bracero J, Rivera A, Shieh WJ, Bhatnagar J, Rivera-Diez I, Hunsperger E, Munoz-Jordan J, Zaki SR, Tomashek KM.</emphasis> 2012. Fatal human co-infection with <citetitle><emphasis>Leptospira</emphasis></citetitle> spp. and dengue virus, Puerto Rico, 2010. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">18:</emphasis>878–880.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Lopez Rodriguez E, Tomashek KM, Gregory CJ, Munoz J, Hunsperger E, Lorenzi OD, Irizarry JG, Garcia-Gubern C.</emphasis> 2010. Co-infection with dengue virus and pandemic H1N1) 2009 virus. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">16:</emphasis>882–884.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Epelboin L, Hanf M, Dussart P, Ouar-Epelboin S, Djossou F, Nacher M, Carme B.</emphasis> 2012. Is dengue and malaria co-infection more severe than single infections? A retrospective matched-pair study in French Guiana. <citetitle><emphasis>Malar J</emphasis></citetitle> <emphasis role="strong">11:</emphasis>142.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Paz-Bailey G, Rosenberg ES, Doyle K, Munoz-Jordan J, Santiago GA, Klein L, Perez-Padilla J, Medina FA, Waterman SH, Gubern CG, Alvarado LI, Sharp TM.</emphasis> 2017. Persistence of Zika virus in body fluids - final report. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">379:</emphasis>1234–1243.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Anders KL, Nguyet NM, Quyen NTH, Ngoc TV, Tram TV, Gan TT, Tung NT, Dung NT, Chau NVV, Wills B, Simmons CP.</emphasis> 2012. An evaluation of dried blood spots and oral swabs as alternative specimens for the diagnosis of dengue and screening for past dengue virus exposure. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">87:</emphasis>165–170.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Bharucha T, Chanthongthip A, Phuangpanom S, Phonemixay O, Sengvilaipaseuth O, Vongsouvath M, Lee S, Newton PN, Dubot-Pérès A.</emphasis> 2016. Pre-cut filter paper for detecting anti-Japanese encephalitis virus IgM from dried cerebrospinal fluid spots. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e0004516.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Lanciotti RS, Kerst AJ, Nasci RS, Godsey MS, Mitchell CJ, Savage HM, Komar N, Panella NA, Allen BC, Volpe KE, Davis BS, Roehrig JT.</emphasis> 2000. Rapid detection of west nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>4066–4071.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Lindsey NP, Fischer M, Neitzel D, Schiffman E, Salas ML, Glaser CA, Sylvester T, Kretschmer M, Bunko A, Staples JE.</emphasis> 2016. Hospital-based enhanced surveillance for West Nile virus neuroinvasive disease. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">144:</emphasis>3170–3175.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Garcia MN, Hasbun R, Murray KO.</emphasis> 2015. Persistence of West Nile virus. <citetitle><emphasis>Microbes Infect</emphasis></citetitle> <emphasis role="strong">17:</emphasis>163–168.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Oshiro LS, Dondero DV, Emmons RW, Lennette EH.</emphasis> 1978. The development of Colorado tick fever virus within cells of the haemopoietic system. <citetitle><emphasis>J Gen Virol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>73–79.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Hughes LE, Casper EA, Clifford CM.</emphasis> 1974. Persistence of Colorado tick fever virus in red blood cells. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">23:</emphasis>530–532.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Bingham AM, Cone M, Mock V, Heberlein-Larson L, Stanek D, Blackmore C, Likos A.</emphasis> 2016. Comparison of test results for Zika virus RNA in urine, serum, and saliva specimens from persons with travel-associated Zika virus disease - Florida, 2016. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">65:</emphasis>475–478.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Mead PS, Duggal NK, Hook SA, Delorey M, Fischer M, Olzenak McGuire D, Becksted H, Max RJ, Anishchenko M, Schwartz AM, Tzeng WP, Nelson CA, McDonald EM, Brooks JT, Brault AC, Hinckley AF.</emphasis> 2018. Zika virus shedding in semen of symptomatic infected men. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">378:</emphasis>1377–1385.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Prince HE, Tobler LH, Yeh C, Gefter N, Custer B, Busch MP.</emphasis> 2007. Persistence of West Nile virus-specific antibodies in viremic blood donors. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">14:</emphasis>1228–1230.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Tan CH, Wong PS, Li MZ, Vythilingam I, Ng LC.</emphasis> 2011. Evaluation of the Dengue NS1 Ag Strip<superscript>®</superscript> for detection of dengue virus antigen in <citetitle><emphasis>Aedes aegypti</emphasis></citetitle> Diptera: Culicidae). <citetitle><emphasis>Vector Borne Zoonotic Dis</emphasis></citetitle> <emphasis role="strong">11:</emphasis>789–792.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Sutherland GL, Nasci RS.</emphasis> 2007. Detection of West Nile virus in large pools of mosquitoes. <citetitle><emphasis>J Am Mosq Control Assoc</emphasis></citetitle> <emphasis role="strong">23:</emphasis>389–395.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Wanja E, Parker Z, Rowland T, Turell MJ, Clark JW, Davé K, Davé S, Sang R.</emphasis> 2011. Field evaluation of a wicking assay for the rapid detection of Rift Valley fever viral antigens in mosquitoes. <citetitle><emphasis>J Am Mosq Control Assoc</emphasis></citetitle> <emphasis role="strong">27:</emphasis>370–375.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Hayat MA.</emphasis> 2000. <citetitle><emphasis>Principles and Techniques of Electron Microscopy</emphasis></citetitle>, 4th ed. Cambridge University Press, Cambridge, UK.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Bozzola JJ, Russell LD.</emphasis> 1999. <citetitle><emphasis>Electron Microscopy: Principles and Techniques for Biologists: Biological Applications.</emphasis></citetitle> Jones and Bartlett Learning, Sudbury, MA.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Johnson RT, Burke DS, Elwell M, Leake CJ, Nisalak A, Hoke CH, Lorsomrudee W.</emphasis> 1985. Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. <citetitle><emphasis>Ann Neurol</emphasis></citetitle> <emphasis role="strong">18:</emphasis>567–573.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Burke DS, Lorsomrudee W, Leake CJ, Hoke CH, Nisalak A, Chongswasdi V, Laorakpongse T.</emphasis> 1985. Fatal outcome in Japanese encephalitis. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">34:</emphasis>1203–1210.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Basílio-de-Oliveira CA, Aguiar GR, Baldanza MS, Barth OM, Eyer-Silva WA, Paes MV.</emphasis> 2005. Pathologic study of a fatal case of dengue-3 virus infection in Rio de Janeiro, Brazil. <citetitle><emphasis>Braz J Infect Dis</emphasis></citetitle> <emphasis role="strong">9:</emphasis>341–347.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">De Brito T, Siqueira SA, Santos RT, Nassar ES, Coimbra TL, Alves VA.</emphasis> 1992. Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart. <citetitle><emphasis>Pathol Res Pract</emphasis></citetitle> <emphasis role="strong">188:</emphasis>177–181.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Deubel V, Huerre M, Cathomas G, Drouet MT, Wuscher N, Le Guenno B, Widmer AF.</emphasis> 1997. Molecular detection and characterization of yellow fever virus in blood and liver specimens of a non-vaccinated fatal human case. <citetitle><emphasis>J Med Virol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>212–217.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Bhatnagar J, Guarner J, Paddock CD, Shieh WJ, Lanciotti RS, Marfin AA, Campbell GL, Zaki SR.</emphasis> 2007. Detection of West Nile virus in formalin-fixed, paraffin-embedded human tissues by RT-PCR: a useful adjunct to conventional tissue-based diagnostic methods. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>106–111.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Wanja E, Parker ZF, Odusami O, Rowland T, Davé K, Davé S, Turell MJ.</emphasis> 2014. Immuno-chromatographic wicking assay for the rapid detection of dengue viral antigens in mosquitoes Diptera: Culicidae). <citetitle><emphasis>J Med Entomol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>220–225.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Ryan J, Davé K, Emmerich E, Fernández B, Turell M, Johnson J, Gottfried K, Burkhalter K, Kerst A, Hunt A, Wirtz R, Nasci R.</emphasis> 2003. Wicking assays for the rapid detection of West Nile and St. Louis encephalitis viral antigens in mosquitoes Diptera: Culicidae). <citetitle><emphasis>J Med Entomol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>95–99.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Niklasson BS, Gargan TP II.</emphasis> 1985. Enzyme-linked immunosorbent assay for detection of Rift Valley fever virus antigen in mosquitoes. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">34:</emphasis>400–405.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Brown TM, Mitchell CJ, Nasci RS, Smith GC, Roehrig JT.</emphasis> 2001. Detection of eastern equine encephalitis virus in infected mosquitoes using a monoclonal antibody-based antigen-capture enzyme-linked immunosorbent assay. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">65:</emphasis>208–213.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Santoso MS, Yohan B, Denis D, Hayati RF, Haryanto S, Trianty L, Noviyanti R, Hibberd ML, Sasmono RT.</emphasis> 2020. Diagnostic accuracy of 5 different brands of dengue virus non-structural protein 1 NS1) antigen rapid diagnostic tests RDT) in Indonesia. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">98:</emphasis>115116.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Suzuki K, Nakayama EE, Saito A, Egawa A, Sato T, Phadungsombat J, Rahim R, Hasan A, Iwamoto H, Rahman M, Shioda T.</emphasis> 2019. Evaluation of novel rapid detection kits for dengue virus NS1 antigen in Dhaka, Bangladesh, in 2017. <citetitle><emphasis>Virol J</emphasis></citetitle> <emphasis role="strong">16:</emphasis>102.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Young PR, Hilditch PA, Bletchly C, Halloran W.</emphasis> 2000. An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>1053–1057.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, Flamand M.</emphasis> 2002. Enzyme-linked immunosorbent assay specific to dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>376–381.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, Vaughn DW, Nisalak A, Ennis FA, Rothman AL.</emphasis> 2002. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">186:</emphasis>1165–1168.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Puerta-Guardo H, Glasner DR, Harris E.</emphasis> 2016. Dengue virus NS1 disrupts the endothelial glycocalyx, leading to hyperpermeability. <citetitle><emphasis>PLoS Pathog</emphasis></citetitle> <emphasis role="strong">12:</emphasis>e1005738.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Xu H, Di B, Pan YX, Qiu LW, Wang YD, Hao W, He LJ, Yuen KY, Che XY.</emphasis> 2006. Serotype 1-specific monoclonal antibody-based antigen capture immunoassay for detection of circulating nonstructural protein NS1: implications for early diagnosis and serotyping of dengue virus infections. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>2872–2878.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Buonora SN, Dos Santos FB, Daumas RP, Passos SR, da Silva MH, de Lima MR, Nogueira RM.</emphasis> 2017. Increased sensitivity of NS1 ELISA by heat dissociation in acute dengue 4 cases. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>204.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Bessoff K, Delorey M, Sun W, Hunsperger E.</emphasis> 2008. Comparison of two commercially available dengue virus DENV) NS1 capture enzyme-linked immunosorbent assays using a single clinical sample for diagnosis of acute DENV infection. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">15:</emphasis>1513–1518.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Blacksell SD, Mammen MP Jr, Thongpaseuth S, Gibbons RV, Jarman RG, Jenjaroen K, Nisalak A, Phetsouvanh R, Newton PN, Day NP.</emphasis> 2008. Evaluation of the Panbio dengue virus nonstructural 1 antigen detection and immunoglobulin M antibody enzyme-linked immunosorbent assays for the diagnosis of acute dengue infections in Laos. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">60:</emphasis>43–49.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Dussart P, Labeau B, Lagathu G, Louis P, Nunes MR, Rodrigues SG, Storck-Herrmann C, Cesaire R, Morvan J, Flamand M, Baril L.</emphasis> 2006. Evaluation of an enzyme immunoassay for detection of dengue virus NS1 antigen in human serum. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">13:</emphasis>1185–1189.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Kumarasamy V, Wahab AH, Chua SK, Hassan Z, Chem YK, Mohamad M, Chua KB.</emphasis> 2007. Evaluation of a commercial dengue NS1 antigen-capture ELISA for laboratory diagnosis of acute dengue virus infection. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">140:</emphasis>75–79.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Steinhagen K, Probst C, Radzimski C, Schmidt-Chanasit J, Emmerich P, van Esbroeck M, Schinkel J, Grobusch MP, Goorhuis A, Warnecke JM, Lattwein E, Komorowski L, Deerberg A, Saschenbrecker S, Stöcker W, Schlumberger W.</emphasis> 2016. Serodiagnosis of Zika virus ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a multicohort study of assay performance, 2015 to 2016. <citetitle><emphasis>Euro Surveill</emphasis></citetitle> <emphasis role="strong">21:</emphasis>30426.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV.</emphasis> 1992. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">30:</emphasis>545–551.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Patel P, Landt O, Kaiser M, Faye O, Koppe T, Lass U, Sall AA, Niedrig M.</emphasis> 2013. Development of one-step quantitative reverse transcription PCR for the rapid detection of flaviviruses. <citetitle><emphasis>Virol J</emphasis></citetitle> <emphasis role="strong">10:</emphasis>58.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Lambert AJ, Lanciotti RS.</emphasis> 2009. Consensus amplification and novel multiplex sequencing method for S segment species identification of 47 viruses of the Orthobunyavirus, Phlebovirus, and Nairovirus genera of the family Bunyaviridae. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>2398–2404.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Pabbaraju K, Wong S, Gill K, Fonseca K, Tipples GA, Tellier R.</emphasis> 2016. Simultaneous detection of Zika, chikungunya and dengue viruses by a multiplex real-time RT-PCR assay. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">83:</emphasis>66–71.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Waggoner JJ, Gresh L, Mohamed-Hadley A, Ballesteros G, Davila MJ, Tellez Y, Sahoo MK, Balmaseda A, Harris E, Pinsky BA.</emphasis> 2016. Single-reaction multiplex reverse transcription PCR for detection of Zika, chikungunya, and dengue Viruses. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>1295–1297.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Liu J, Ochieng C, Wiersma S, Ströher U, Towner JS, Whitmer S, Nichol ST, Moore CC, Kersh GJ, Kato C, Sexton C, Petersen J, Massung R, Hercik C, Crump JA, Kibiki G, Maro A, Mujaga B, Gratz J, Jacob ST, Banura P, Scheld WM, Juma B, Onyango CO, Montgomery JM, Houpt E, Fields B.</emphasis> 2016. Development of a TaqMan array card for acute-febrile-illness outbreak investigation and surveillance of emerging pathogens, including Ebola virus. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>49–58.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Manabe YC, Betz J, Jackson O, Asoala V, Bazan I, Blair PW, Chang A, Chusri S, Crump JA, Edgel KA, Faix DJ, Fernandez S, Fox AT, Garcia JA, Grogl M, Hansen EA, Heang V, House SL, Jongsakul K, Kaburise MB, Klungthong C, Lamorde M, Letizia AG, Lorenzana I, Luy M, Maro VP, Mores CN, Myers CA, Oduro AR, Parham L, Porzucek AJ, Prouty M, Rabiger DS, Rubach MP, Siles C, Silva M, Ukachu C, Waitumbi JN, Phillips CL, Jones BW.</emphasis> 2022. Clinical evaluation of the BioFire Global Fever Panel for the identification of malaria, leptospirosis, chikungunya, and dengue from whole blood: a prospective, multicentre, cross-sectional diagnostic accuracy study. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>1356–1364.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Calvert AE, Biggerstaff BJ, Tanner NA, Lauterbach M, Lanciotti RS.</emphasis> 2017. Rapid colorimetric detection of Zika virus from serum and urine specimens by reverse transcription loop-mediated isothermal amplification RT-LAMP). <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">12:</emphasis>e0185340.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Toriniwa H, Komiya T.</emphasis> 2006. Rapid detection and quantification of Japanese encephalitis virus by real-time reverse transcription loop-mediated isothermal amplification. <citetitle><emphasis>Microbiol Immunol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>379–387.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Parida M, Horioke K, Ishida H, Dash PK, Saxena P, Jana AM, Islam MA, Inoue S, Hosaka N, Morita K.</emphasis> 2005. Rapid detection and differentiation of dengue virus serotypes by a real-time reverse transcription-loop-mediated isothermal amplification assay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>2895–2903.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Parida MM, Santhosh SR, Dash PK, Tripathi NK, Saxena P, Ambuj S, Sahni AK, Lakshmana Rao PV, Morita K.</emphasis> 2006. Development and evaluation of reverse transcription-loop-mediated isothermal amplification assay for rapid and real-time detection of Japanese encephalitis virus. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>4172–4178.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Nunes MR, Vianez JL Jr, Nunes KN, da Silva SP, Lima CP, Guzman H, Martins LC, Carvalho VL, Tesh RB, Vasconcelos PF.</emphasis> 2015. Analysis of a reverse transcription loop-mediated isothermal amplification (RT-LAMP) for yellow fever diagnostic. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">226:</emphasis>40–51.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Kinsella CM, Paras ML, Smole S, Mehta S, Ganesh V, Chen LH, McQuillen DP, Shah R, Chan J, Osborne M, Hennigan S, Halpern-Smith F, Brown CM, Sabeti P, Piantadosi A.</emphasis> 2020. Jamestown Canyon virus in Massachusetts: clinical case series and vector screening. <citetitle><emphasis>Emerg Microbes Infect</emphasis></citetitle> <emphasis role="strong">9:</emphasis>903–912.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Miller S, Naccache SN, Samayoa E, Messacar K, Arevalo S, Federman S, Stryke D, Pham E, Fung B, Bolosky WJ, Ingebrigtsen D, Lorizio W, Paff SM, Leake JA, Pesano R, DeBiasi R, Dominguez S, Chiu CY.</emphasis> 2019. Laboratory validation of a clinical metagenomic sequencing assay for pathogen detection in cerebrospinal fluid. <citetitle><emphasis>Genome Res</emphasis></citetitle> <emphasis role="strong">29:</emphasis>831–842.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Hughes HR, Velez JO, Davis EH, Laven J, Gould CV, Panella AJ, Lambert AJ, Staples JE, Brault AC.</emphasis> 2021. Fatal human infection with evidence of intrahost variation of eastern equine encephalitis virus, Alabama, USA, 2019. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">27:</emphasis>1886–1892.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Solomon IH, Ganesh VS, Yu G, Deng XD, Wilson MR, Miller S, Milligan TA, Mukerji SS, Mathewson A, Linxweiler J, Morse D, Ritter JM, Staples JE, Hughes H, Gould CV, Sabeti PC, Chiu CY, Piantadosi A.</emphasis> 2021. Fatal case of chronic Jamestown Canyon virus encephalitis diagnosed by metagenomic sequencing in patient receiving rituximab. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">27:</emphasis>238-242.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Solomon IH, Spera KM, Ryan SL, Helgager J, Andrici J, Zaki SR, Vaitkevicius H, Leon KE, Wilson MR, DeRisi JL, Koo S, Smirnakis SM, De Girolami U.</emphasis> 2018. Fatal Powassan encephalitis (deer tick virus, lineage II) in a patient with fever and orchitis receiving rituximab. <citetitle><emphasis>JAMA Neurol</emphasis></citetitle> <emphasis role="strong">75:</emphasis>746–750.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Steininger PA, Bobinger T, Dietrich W, Lee DH, Knott M, Bogdan C, Korn K, Lang R.</emphasis> 2017. Two cases of severe tick-borne encephalitis in rituximab-treated patients in Germany: implications for diagnosis and prevention. <citetitle><emphasis>Open Forum Infect Dis</emphasis></citetitle> <emphasis role="strong">4:</emphasis>ofx204.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Huang C, Slater B, Rudd R, Parchuri N, Hull R, Dupuis M, Hindenburg A.</emphasis> 2002. First isolation of West Nile virus from a patient with encephalitis in the United States. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">8:</emphasis>1367–1371.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Jenkins GM, Rambaut A, Pybus OG, Holmes EC.</emphasis> 2002. Rates of molecular evolution in RNA viruses: a quantitative phylogenetic analysis. <citetitle><emphasis>J Mol Evol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>156–165.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Tabachnick WJ.</emphasis> 2013. Nature, nurture and evolution of intra-species variation in mosquito arbovirus transmission competence. <citetitle><emphasis>Int J Environ Res Public Health</emphasis></citetitle> <emphasis role="strong">10:</emphasis>249–277.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Igarashi A.</emphasis> 1978. Isolation of a Singh’s <citetitle><emphasis>Aedes albopictus</emphasis></citetitle> cell clone sensitive to dengue and chikungunya viruses. <citetitle><emphasis>J Gen Virol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>531–544.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Varma MG, Pudney M, Leake CJ.</emphasis> 1974. Cell lines from larvae of <citetitle><emphasis>Aedes</emphasis></citetitle> (<citetitle><emphasis>Stegomyia</emphasis></citetitle>) <citetitle><emphasis>malayensis</emphasis></citetitle> Colless and <citetitle><emphasis>Aedes</emphasis></citetitle> (<citetitle><emphasis>S</emphasis></citetitle>) <citetitle><emphasis>pseudoscutellaris</emphasis></citetitle> (Theobald) and their infection with some arboviruses. <citetitle><emphasis>Trans R Soc Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">68:</emphasis>374–382.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Weaver SC, Reisen WK.</emphasis> 2010. Present and future arboviral threats. <citetitle><emphasis>Antiviral Res</emphasis></citetitle> <emphasis role="strong">85:</emphasis>328–345.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Swei A, Russell BJ, Naccache SN, Kabre B, Veeraraghavan N, Pilgard MA, Johnson BJ, Chiu CY.</emphasis> 2013. The genome sequence of Lone Star virus, a highly divergent bunyavirus found in the <citetitle><emphasis>Amblyomma americanum</emphasis></citetitle> tick. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e62083.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Clarke DH, Casals J.</emphasis> 1958. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">7:</emphasis>561–573.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Hunsperger EA, Muñoz-Jordán J, Beltran M, Colón C, Carrión J, Vazquez J, Acosta LN, Medina-Izquierdo JF, Horiuchi K, Biggerstaff BJ, Margolis HS.</emphasis> 2016. Performance of dengue diagnostic tests in a single-specimen diagnostic algorithm. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">214:</emphasis>836–844.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH.</emphasis> 1989. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">40:</emphasis>418–427.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Miagostovich MP, Nogueira RMR, dos Santos FB, Schatzmayr HG, Araújo ESM, Vorndam V.</emphasis> 1999. Evaluation of an IgG enzyme-linked immunosorbent assay for dengue diagnosis. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">14:</emphasis>183–189.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Chanama S, Sukprasert W, Sa-ngasang A, A-nuegoonpipat A, Sangkitporn S, Kurane I, Anantapreecha S.</emphasis> 2005. Detection of Japanese encephalitis (JE) virus-specific IgM in cerebrospinal fluid and serum samples from JE patients. <citetitle><emphasis>Jpn J Infect Dis</emphasis></citetitle> <emphasis role="strong">58:</emphasis>294–296.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S.</emphasis> 1985. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">151:</emphasis>1093–1099.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Ravi V, Desai AS, Shenoy PK, Satishchandra P, Chandramuki A, Gourie-Devi M.</emphasis> 1993. Persistence of Japanese encephalitis virus in the human nervous system. <citetitle><emphasis>J Med Virol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>326–329.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Prince HE, Tobler LH, Lapé-Nixon M, Foster GA, Stramer SL, Busch MP.</emphasis> 2005. Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>4316–4320.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Edelman R, Schneider RJ, Vejjajiva A, Pornpibul R, Voodhikul P.</emphasis> 1976. Persistence of virus-specific IgM and clinical recovery after Japanese encephalitis. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">25:</emphasis>733–738.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Kapoor H, Signs K, Somsel P, Downes FP, Clark PA, Massey JP.</emphasis> 2004. Persistence of West Nile virus (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">31:</emphasis>289–291.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Staples JE, Gibney KB, Panella AJ, Prince HE, Basile AJ, Laven J, Sejvar JJ, Fischer M.</emphasis> 2022. Duration of West Nile virus immunoglobulin M antibodies up to 81 months following West Nile virus disease onset. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">106:</emphasis>1721–1724.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Levett PN, Sonnenberg K, Sidaway F, Shead S, Niedrig M, Steinhagen K, Horsman GB, Drebot MA.</emphasis> 2005. Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>5873–5875.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, Pelegrino JL, Vázquez S, Artsob H, Drebot M, Gubler DJ, Halstead SB, Guzmán MG, Margolis HS, Nathanson C-M, Rizzo Lic NR, Bessoff KE, Kliks S, Peeling RW.</emphasis> 2009. Evaluation of commercially available anti-dengue virus immunoglobulin M tests. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>436–440.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Blacksell SD, Bell D, Kelley J, Mammen MP Jr, Gibbons RV, Jarman RG, Vaughn DW, Jenjaroen K, Nisalak A, Thongpaseuth S, Vongsouvath M, Davong V, Phouminh P, Phetsouvanh R, Day NPJ, Newton PN.</emphasis> 2007. Prospective study to determine accuracy of rapid serological assays for diagnosis of acute dengue virus infection in Laos. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">14:</emphasis>1458–1464.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Ravi V, Robinson JS, Russell BJ, Desai A, Ramamurty N, Featherstone D, Johnson BW.</emphasis> 2009. Evaluation of IgM antibody capture enzyme-linked immunosorbent assay kits for detection of IgM against Japanese encephalitis virus in cerebrospinal fluid samples. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">81:</emphasis>1144–1150.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">WHO.</emphasis> 2009. <citetitle><emphasis>Evaluation of Commercially Available Anti-Dengue Virus Immunoglobulin M Tests.</emphasis></citetitle> World Health Organization, Geneva, Switzerland.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Imrie A, Meeks J, Gurary A, Sukhbaatar M, Truong TT, Cropp CB, Effler P.</emphasis> 2007. Antibody to dengue 1 detected more than 60 years after infection. <citetitle><emphasis>Viral Immunol</emphasis></citetitle> <emphasis role="strong">20:</emphasis>672–675.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Johnson AJ, Martin DA, Karabatsos N, Roehrig JT.</emphasis> 2000. Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>1827–1831.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Moreira-Soto A, de Souza Sampaio G, Pedroso C, Postigo-Hidalgo I, Berneck BS, Ulbert S, Brites C, Netto EM, Drexler JF.</emphasis> 2020. Rapid decline of Zika virus NS1 antigen-specific antibody responses, northeastern Brazil. <citetitle><emphasis>Virus Genes</emphasis></citetitle> <emphasis role="strong">56:</emphasis>632–637.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Cardosa MJ, Wang SM, Sum MSH, Tio PH.</emphasis> 2002. Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. <citetitle><emphasis>BMC Microbiol</emphasis></citetitle> <emphasis role="strong">2:</emphasis>9.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">dos Santos FB, Miagostovich MP, Nogueira RMR, Schatzmayr HG, Riley LW, Harris E.</emphasis> 2004. Analysis of recombinant dengue virus polypeptides for dengue diagnosis and evaluation of the humoral immune response. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">71:</emphasis>144–152.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Matheus S, Deparis X, Labeau B, Lelarge J, Morvan J, Dussart P.</emphasis> 2005. Discrimination between primary and secondary dengue virus infection by an immunoglobulin G avidity test using a single acute-phase serum sample. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>2793–2797.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Cordeiro MT, Braga-Neto U, Nogueira RMR, Marques ETA Jr.</emphasis> 2009. Reliable classifier to differentiate primary and secondary acute dengue infection based on IgG ELISA. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">4:</emphasis>e4945.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">de Souza VAUF, Fernandes S, Araújo ES, Tateno AF, Oliveira OMNPF, Oliveira RR, Pannuti CS.</emphasis> 2004. Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1782–1784.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Simmons G, Stone M, Busch MP.</emphasis> 2018. Arbovirus diagnostics: from bad to worse due to expanding dengue virus vaccination and Zika virus epidemics. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1181–1183.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Speer SD, Pierson TC.</emphasis> 2016. Diagnostics for Zika virus on the horizon. <citetitle><emphasis>Science</emphasis></citetitle> <emphasis role="strong">353:</emphasis>750–751.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Pereira SS, Andreata-Santos R, Pereira LR, Soares CP, Félix AC, de Andrade PMJC, Durigon EL, Romano CM, Ferreira LCS.</emphasis> 2021. NS1-based ELISA test efficiently detects dengue infections without cross-reactivity with Zika virus. <citetitle><emphasis>Int J Infect Dis</emphasis></citetitle> <emphasis role="strong">112:</emphasis>202–204.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Kabir MA, Zilouchian H, Sher M, Asghar W.</emphasis> 2020. Development of a flow-free automated colorimetric detection assay integrated with smartphone for Zika NS1. <citetitle><emphasis>Diagnostics (Basel)</emphasis></citetitle> <emphasis role="strong">10:</emphasis>42.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Lustig Y, Zelena H, Venturi G, Van Esbroeck M, Rothe C, Perret C, Koren R, Katz-Likvornik S, Mendelson E, Schwartz E.</emphasis> 2017. Sensitivity and kinetics of an NS1-based Zika virus enzyme-linked immunosorbent assay in Zika virus-infected travelers from Israel, the Czech Republic, Italy, Belgium, Germany, and Chile. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1894–1901.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Thakare JP, Gore MM, Risbud AR, Banerjee K, Ghosh SN.</emphasis> 1991. Detection of virus specific IgG subclasses in Japanese encephalitis patients. <citetitle><emphasis>Indian J Med Res</emphasis></citetitle> <emphasis role="strong">93:</emphasis>271–276.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Koraka P, Suharti C, Setiati TE, Mairuhu ATA, Van Gorp E, Hack CE, Juffrie M, Sutaryo J, Van Der Meer GM, Groen J, Osterhaus ADME.</emphasis> 2001. Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>4332–4338.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Thein S, Aaskov J, Myint TT, Shwe TN, Saw TT, Zaw A.</emphasis> 1993. Changes in levels of anti-dengue virus IgG subclasses in patients with disease of varying severity. <citetitle><emphasis>J Med Virol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>102–106.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, Pinsky BA, Chokephaibulkit K, Onlamoon N, Pattanapanyasat K, Taubenberger JK, Ahmed R, Ravetch JV.</emphasis> 2017. IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity. <citetitle><emphasis>Science</emphasis></citetitle> <emphasis role="strong">355:</emphasis>395–398.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Mortimer PP, Parry JV.</emphasis> 1988. The use of saliva for viral diagnosis and screening. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">101:</emphasis>197–201.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Faustini SE, Jossi SE, Perez-Toledo M, Shields AM, Allen JD, Watanabe Y, Newby ML, Cook A, Willcox CR, Salim M, Goodall M, Heaney JL, Marcial-Juarez E, Morley GL, Torlinska B, Wraith DC, Veenith TV, Harding S, Jolles S, Ponsford MJ, Plant T, Huissoon A, O’Shea MK, Willcox BE, Drayson MT, Crispin M, Cunningham AF, Richter AG.</emphasis> 2021. Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva. <citetitle><emphasis>Immunology</emphasis></citetitle> <emphasis role="strong">164:</emphasis>135–147.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Balmaseda A, Guzmán MG, Hammond S, Robleto G, Flores C, Téllez Y, Videa E, Saborio S, Pérez L, Sandoval E, Rodriguez Y, Harris E.</emphasis> 2003. Diagnosis of dengue virus infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum and saliva. <citetitle><emphasis>Clin Diagn Lab Immunol</emphasis></citetitle> <emphasis role="strong">10:</emphasis>317–322.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Talarmin A, Labeau B, Lelarge J, Sarthou JL.</emphasis> 1998. Immunoglobulin A-specific capture enzyme-linked immunosorbent assay for diagnosis of dengue fever. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>1189–1192.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Prasad SR, Yergolkar PN, Walhekar BD, Dandawate CN.</emphasis> 1994. Virus specific IgM, IgG and IgA antibodies in serum and saliva of Japanese encephalitis patients. <citetitle><emphasis>Indian J Pediatr</emphasis></citetitle> <emphasis role="strong">61:</emphasis>109–110.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Han XY, Ren QW, Xu ZY, Tsai TF.</emphasis> 1988. Serum and cerebrospinal fluid immunoglobulins M, A, and G in Japanese encephalitis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">26:</emphasis>976–978.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Blitvich BJ, Bowen RA, Marlenee NL, Hall RA, Bunning ML, Beaty BJ.</emphasis> 2003. Epitope-blocking enzyme-linked immunosorbent assays for detection of West Nile virus antibodies in domestic mammals. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>2676–2679.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Balmaseda A, Stettler K, Medialdea-Carrera R, Collado D, Jin X, Zambrana JV, Jaconi S, Cameroni E, Saborio S, Rovida F, Percivalle E, Ijaz S, Dicks S, Ushiro-Lumb I, Barzon L, Siqueira P, Brown DWG, Baldanti F, Tedder R, Zambon M, de Filippis AMB, Harris E, Corti D.</emphasis> 2017. Antibody-based assay discriminates Zika virus infection from other flaviviruses. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">114:</emphasis>8384–8389.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Goh LY, Kam YW, Metz SW, Hobson-Peters J, Prow NA, McCarthy S, Smith DW, Pijlman GP, Ng LF, Hall RA.</emphasis> 2015. A sensitive epitope-blocking ELISA for the detection of Chikungunya virus-specific antibodies in patients. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">222:</emphasis>55–61.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E.</emphasis> 2017. Antibody-dependent enhancement of severe dengue disease in humans. <citetitle><emphasis>Science</emphasis></citetitle> <emphasis role="strong">358:</emphasis>929–932.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Johnson AJ, Noga AJ, Kosoy O, Lanciotti RS, Johnson AA, Biggerstaff BJ.</emphasis> 2005. Duplex microsphere-based immunoassay for detection of anti-West Nile virus and anti-St. Louis encephalitis virus immunoglobulin m antibodies. <citetitle><emphasis>Clin Diagn Lab Immunol</emphasis></citetitle> <emphasis role="strong">12</emphasis>(5):566–574.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Johnson AJ, Cheshier RC, Cosentino G, Masri HP, Mock V, Oesterle R, Lanciotti RS, Martin DA, Panella AJ, Kosoy O, Biggerstaff BJ.</emphasis> 2007. Validation of a microsphere-based immunoassay for detection of anti-West Nile virus and anti-St. Louis encephalitis virus immunoglobulin m antibodies. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">14</emphasis>(<link linkend="ch0117s0009s0002li0009">9</link>)<emphasis role="strong">:</emphasis>1084–1093.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Basile AJ, Horiuchi K, Panella AJ, Laven J, Kosoy O, Lanciotti RS, Venkateswaran N, Biggerstaff BJ.</emphasis> 2013. Multiplex microsphere immunoassays for the detection of IgM and IgG to arboviral diseases. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8</emphasis>(9):e75670.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Brown SC, Cormier J, Tuan J, Lier AJ, McGuone D, Armstrong PM, Kaddouh F, Parikh S, Landry ML, Gobeske KT.</emphasis> 2021. Four human cases of Eastern equine encephalitis in Connecticut, USA, during a larger regional outbreak, 2019. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">27</emphasis>(<link linkend="ch0117s0009s0002li0008">8</link>)<emphasis role="strong">:</emphasis>2042–2051.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Banoo S, Bell D, Bossuyt P, Herring A, Mabey D, Poole F, Smith PG, Sriram N, Wongsrichanalai C, Linke R, O’Brien R, Perkins M, Cunningham J, Matsoso P, Nathanson CM, Olliaro P, Peeling RW, Ramsay A, Ramsay A, TDR Diagnostics Evaluation Expert Panel.</emphasis> 2010. Evaluation of diagnostic tests for infectious diseases: general principles. <citetitle><emphasis>Nat Rev Microbiol</emphasis></citetitle> <emphasis role="strong">8</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S17–S29.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Modis Y, Ogata S, Clements D, Harrison SC.</emphasis> 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. <citetitle><emphasis>J Virol</emphasis></citetitle> <emphasis role="strong">79:</emphasis>1223–1231.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Roehrig JT, Bolin RA, Kelly RG.</emphasis> 1998. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. <citetitle><emphasis>Virology</emphasis></citetitle> <emphasis role="strong">246:</emphasis>317–328.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Crill WD, Roehrig JT.</emphasis> 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. <citetitle><emphasis>J Virol</emphasis></citetitle> <emphasis role="strong">75:</emphasis>7769–7773.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Roehrig JT, Mathews JH.</emphasis> 1985. The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes. <citetitle><emphasis>Virology</emphasis></citetitle> <emphasis role="strong">142:</emphasis>347–356.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Hunt AR, Frederickson S, Maruyama T, Roehrig JT, Blair CD.</emphasis> 2010. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">4:</emphasis>e739.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Cheng LL, Schultz KT, Yuill TM, Israel BA.</emphasis> 2000. Identification and localization of conserved antigenic epitopes on the G2 proteins of California serogroup bunyaviruses. <citetitle><emphasis>Viral Immunol</emphasis></citetitle> <emphasis role="strong">13:</emphasis>201–213.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Westaway EG.</emphasis> 1965. The neutralization of arboviruses. II. Neutralization in heterologous virus-serum mixtures with four group B arboviruses. <citetitle><emphasis>Virology</emphasis></citetitle> <emphasis role="strong">26:</emphasis>528–537.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Westaway EG.</emphasis> 1965. The neutralization of arboviruses. I. Neutralization homologous virus-serum mixtures with two group B arboviruses. <citetitle><emphasis>Virology</emphasis></citetitle> <emphasis role="strong">26:</emphasis>517–527.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">Halstead SB, O’Rourke EJ.</emphasis> 1977. Antibody-enhanced dengue virus infection in primate leukocytes. <citetitle><emphasis>Nature</emphasis></citetitle> <emphasis role="strong">265:</emphasis>739–741.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Ferenczi E, Bán E, Abrahám A, Kaposi T, Petrányi G, Berencsi G, Vaheri A.</emphasis> 2008. Severe tick-borne encephalitis in a patient previously infected by West Nile virus. <citetitle><emphasis>Scand J Infect Dis</emphasis></citetitle> <emphasis role="strong">40:</emphasis>759–761.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS.</emphasis> 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. <citetitle><emphasis>Cell Host Microbe</emphasis></citetitle> <emphasis role="strong">1:</emphasis>135–145.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Roehrig JT, Hombach J, Barrett ADT.</emphasis> 2008. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. <citetitle><emphasis>Viral Immunol</emphasis></citetitle> <emphasis role="strong">21:</emphasis>123–132.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Hunsperger E, Beltran M, Acosta LN, Jordan-Munoz J, Torres J, Luce R, Tomashek KM.</emphasis> 2011. Serological evaluation of suspected West Nile virus human cases following its introduction during a dengue outbreak in Puerto Rico in 2007. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">18:</emphasis>978–983.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0185" role="bibliographyEntry">
            <para>185.<emphasis role="strong">Calvert AE, Boroughs KL, Laven J, Stovall JL, Luy BE, Kosoy OI, Huang CY.</emphasis> 2018. Incorporation of IgG depletion in a neutralization assay facilitates differential diagnosis of Zika and dengue in secondary flavivirus infection cases. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e00234-18.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0186" role="bibliographyEntry">
            <para>186.<emphasis role="strong">Vorndam V, Beltran M.</emphasis> 2002. Enzyme-linked immunosorbent assay-format microneutralization test for dengue viruses. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">66:</emphasis>208–212.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0187" role="bibliographyEntry">
            <para>187.<emphasis role="strong">Rodrigo WW, Alcena DC, Rose RC, Jin X, Schlesinger JJ, Schlesinger JJ.</emphasis> 2009. An automated Dengue virus microneutralization plaque assay performed in human Fcgamma receptor-expressing CV-1 cells. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">80:</emphasis>61–65.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0188" role="bibliographyEntry">
            <para>188.<emphasis role="strong">Taketa-Graham M, Powell Pereira JL, Baylis E, Cossen C, Oceguera L, Patiris P, Chiles R, Hanson CV, Forghani B.</emphasis> 2010. High throughput quantitative colorimetric microneutralization assay for the confirmation and differentiation of West Nile Virus and St. Louis encephalitis virus. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">82:</emphasis>501–504.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0189" role="bibliographyEntry">
            <para>189.<emphasis role="strong">Putnak JR, de la Barrera R, Burgess T, Pardo J, Dessy F, Gheysen D, Lobet Y, Green S, Endy TP, Thomas SJ, Eckels KH, Innis BL, Sun W.</emphasis> 2008. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">79:</emphasis>115–122.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0190" role="bibliographyEntry">
            <para>190.<emphasis role="strong">Payne AF, Binduga-Gajewska I, Kauffman EB, Kramer LD.</emphasis> 2006. Quantitation of flaviviruses by fluorescent focus assay. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">134:</emphasis>183–189.</para>
          </listitem>
          <listitem id="ch0117s0009s0002li0191" role="bibliographyEntry">
            <para>191.<emphasis role="strong">Whiteman MC, Bogardus L, Giacone DG, Rubinstein LJ, Antonello JM, Sun D, Daijogo S, Gurney KB.</emphasis> 2018. Virus reduction neutralization test: a single-cell imaging high-throughput virus neutralization assay for dengue. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">99:</emphasis>1430–1439.</para>
          </listitem>
        </itemizedlist>
        <anchor id="ch0117s0009s0002a0004"/>
        <beginpage pagenum="1912"/>
        <anchor id="ch0117s0009s0002a0005"/>
        <beginpage pagenum="1913"/>
        <anchor id="ch0117s0009s0002a0006"/>
        <beginpage pagenum="1914"/>
        <anchor id="ch0117s0009s0002a0007"/>
        <beginpage pagenum="1915"/>
        <anchor id="ch0117s0009s0002a0008"/>
        <beginpage pagenum="1916"/>
      </sect2>
    </sect1>
  </chapter>
